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1.0. INTRODUCTION  
1.1. DRUG DELIVERY SYSTEM   
           The treatment of acute diseases or chronic illness has been achieved by 
delivery of drugs to the patients for many years. These drug delivery systems include 
tablets, injectables, suspensions, creams, ointments, liquids and aerosols. Today these 
conventional drug delivery systems are widely used. The term drug delivery can be 
defined as techniques that are used to get the therapeutic agents inside the human 
body.  
Conventional drug therapy requires periodic doses of therapeutic agents. 
These agents are formulated to produce maximum stability, activity and 
bioavailability. For most drugs, conventional methods of drug administration are 
effective, but some drugs are unstable or toxic and have narrow therapeutic window. 
Some drugs also possess solubility problems. In such cases, a method of continuous 
administration of therapeutic agent is desirable to maintain fixed plasma levels as 
shown in figure-1.To overcome these problems, controlled drug delivery systems 
were introduced into the market. These delivery systems have a number of advantages 
over traditional systems such as improved efficiency, reduced toxicity and improved 
patient convenience. The main goal of controlled drug delivery systems is to improve 
the effectiveness of drug therapies1. 
                                            
 Figure-1 Drug levels in the blood with Conventional drug delivery systems and 
Controlled drug delivery systems 
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Most conventional oral drug products, such as tablets and capsules, are formulated to 
release the active drug immediately after oral administration, to obtain rapid and 
complete systemic drug absorption. Such immediate-release products result in 
relatively rapid drug absorption and onset of accompanying Pharmacodynamic 
effects. However, after absorption of the drug from the dosage form is complete, 
plasma drug concentrations decline according to the drug's pharmacokinetic profile. 
Eventually, plasma drug concentrations fall below the minimum effective plasma 
concentration (MEC), resulting in loss of therapeutic activity. In recent years, various 
modified-release drug products have been developed to control the release rate of the 
drug and/or the time for drug release. 
 
The term modified-release drug product is used to describe products that alter the 
timing and/or the rate of release of the drug substance. A modified-release dosage 
form is defined "as one for which the drug-release characteristics of time course 
and/or location are chosen to accomplish therapeutic or convenience objectives not 
offered by conventional dosage forms such as solutions, ointments, or promptly 
dissolving dosage forms as presently recognized2.  
 
Several types of modified-release drug products are recognized: 
 
1. Extended-release drug products. A dosage form that allows at least a two fold 
reduction in dosage frequency as compared to that drug presented as an immediate-
release (conventional) dosage form. Examples of extended-release dosage forms 
include controlled-release, sustained-release, and long-acting drug products.  
 
2. Delayed-release drug products. A dosage form that releases a discrete portion or 
portions of drug at a time or at times other than promptly after administration, 
although one portion may be released promptly after administration. Enteric-coated 
dosage forms are the most common delayed-release products 
 
3. Targeted-release drug products. A dosage form that releases drug at or near the 
intended physiologic site of action. Targeted-release dosage forms may have either 
immediate- or extended-release characteristics. 
 
1.2 DELAYED RELEASE SYSTEMS    
The two types of delayed release systems are: 
1.  Intestinal release systems 
2.  Colonic release system, 
 
1. Intestinal release systems: A drug may be enteric coated for intestinal release for 
several known reasons such as to prevent gastric irritation, prevent destabilization in 
gastric pH  etc. 
   
  Introduction 
Department of Pharmaceutics, R.V.S. College of Pharmaceutical Science 3
2. Colonic release systems: Drugs are poorly absorbed through colon but may be 
delivered to such a site for two reasons 
     a) Local action in the treatment of ulcerative colitis and 
     b) Systemic absorption of protein and peptide drugs  
 
The design of such system involves release of drugs only at a specific site in the 
gastrointestinal tract. The drugs contained in such a system are those that are: 
i)  Destroyed in the stomach or by intestinal enzymes 
ii)  Known to cause gastric distress 
iii)  Absorbed from a specific intestinal site or 
iv)   Meant to exert local effect at a specific gastrointestinal site 
 
                As a result, new strategies of drug delivery have been developed to 
overcome obstacles encountered by oral delivery. Among these strategies, colon-
specific delivery has been extensively studied for the last two decades. Colon, an area 
where protein drugs are free from the attack of numerous proteases, is thought to be 
an ideal location to direct drugs into the bloodstream and the immune system. New 
formulations of different delivery vehicles from synthetic and natural polymers, 
which are either hydrophilic or hydrophobic, have been tested for these purposes. The 
challenge in the design of oral drug delivery vehicles which effectively carry drugs to 
the colon site is to meet a certain criteria. Firstly, they need to remain intact when 
traveling through the upper GI tract in order to protect the incorporated drugs from 
chemical and enzymatic degradation. Secondly, they should be able to release the 
incorporated drugs immediately upon reaching the colon segment of the lower GI 
tract. Furthermore, the released drugs need to be absorbed at an efficient rate in the GI 
tract in order to be therapeutically effective3. 
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1.3 PHYSIOLOGY OF THE GASTROINTESTINAL TRACT4 
 
The gastrointestinal tract is a muscular tube approximately 6 m in length with varying 
diameters. It stretches from the mouth to the anus and consists of four main 
anatomical areas: the oesophagus, the stomach, the small intestine and the large 
intestine or colon. The luminal surface of the tube is not smooth but very rough, 
thereby increasing the surface area for absorption. 
Figure-2 - Physiology of the Gastrointestinal Tract 
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1.3.1The oesophagus 
 
The mouth is the point of entry for most drugs (so called peroral - via the mouth - 
administration). At this point contact with the oral mucosa is usually brief. Linking 
the oral cavity with the stomach is the oesophagus. This is composed of a thick 
muscular layer approximately 250 mm long and 20 mm in diameter. It joins the 
stomach at the gastro esophageal junction, or cardiac orifice as it is sometimes known. 
 
The oesophagus, apart from the lowest 20 mm which is similar to the gastric mucosa, 
contains a well differentiated squamous epithelium of non-proliferative cells. 
Epithelial cell function is mainly protective: simple mucous glands secrete mucus into 
the narrow lumen to lubricate food and protect the lower part of the oesophagus from 
gastric acid. The pH of the oesophageal lumen is usually between 5 and 6. 
 
1.3.2 The stomach 
 
The stomach is the most dilated part of the gastrointestinal tract and is situated 
between the lower end of the oesophagus and the small intestine. Its opening to the 
duodenum is controlled by the pyloric sphincter. The stomach can be divided into four 
anatomical regions, namely the fundus, the body, the antrum and the pylorus. 
 
The stomach has a capacity of approximately 1.5 L, although under fasting conditions 
it usually contains no more than 50 ml of fluid, which are mostly gastric secretions. 
These include: 
• Acid secreted by the parietal cells, which maintains the pH of the stomach 
between 1 and 3.5 in the fasted state; 
• The hormone gastrin, which itself is a potent stimulator of gastric acid 
production. The release of gastrin is stimulated by peptides, amino acids and 
distension of the stomach; 
• Pepsins, which are secreted by the peptic cells in the form of its precursor 
pepsinogen. Pepsins are peptidases which break down proteins to peptides at 
low pH. Above pH 5 pepsin is denatured; 
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• Mucus, which is secreted by the surface mucosal cells and lines the gastric 
mucosa. In the stomach the mucus protects the gastric mucosa from auto 
digestion by the pepsin-acid combination5. 
 
1.3.3 The small intestine 
 
The small intestine is the longest (4-5 m) and most convoluted part of the 
gastrointestinal tract, extending from the pyloric sphincter of the stomach to the 
ileocaecal junction where it joins the large intestine. 
 
Its main functions are: 
• Digestion: the process of enzymatic digestion, which began in the stomach, is 
completed in the small intestine. 
• Absorption: the small intestine is the region where most nutrients and other 
materials are absorbed. The small intestine is divided into the duodenum, 
which is 200-300 mm in length, the jejunum, which is approximately 2 m in 
length, and the ileum, which is approximately 3 m in length. 
 
The surface area of the small intestine is increased enormously, by about 600 times 
that of a  simple cylinder, to approximately 200 m2 in an adult, by several adaptations 
which render the small intestine such a good absorption site: 
•  Folds of Kerckring: these are sub mucosal folds which extend circularly most of 
the way around the intestine and are particularly well developed in the duodenum 
and jejunum. They are several millimeters in depth. 
• Villi: these have been described as finger-like projections into the lumen 
(approximately 0.5-1.5 mm in length and 0.1 mm in diameter).They are well 
supplied with blood vessels. Each villus contains an arteriole, a venule and a blind 
ending lymphatic vessel (lacteal). The structure of a villus. 
• Microvilli: approximately 600-1000 of these brush-like structures (~ 1 μm in 
length and 0.1 μm in width) cover each villus, providing the largest increase in 
surface area. These are covered by a fibrous substance known as glycocalyx. The 
luminal pH of the small intestine increases to between about 6 and 7.5. 
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1.3.4 The colon 6, 7 
Irrespective of therapy desired for local (colonic) or systemic delivery of drug, the 
development and aim of the drug delivery to colon remain same, that is 
• The drug must not absorb from other regions of the gastro intestinal tract      
       (GIT). 
• It should only suffer negligible degradation in the small intestine lumen. 
• The release of the drug in the colon should be at quantitatively controlled rate  
        and the released drug in the colon should be absorbed from the lumen of the  
       large intestine without any appreciable degradation. 
 
Parts of the Colon: 
The colon is actually just another name for the large intestine. The shorter of the two 
intestinal groups, the large intestine, consists of parts with various responsibilities. 
The parts of the colon are; transverse colon, ascending colon, appendix, descending 
colon, sigmoid colon, and the rectum and anus. The transverse, ascending, and 
descending colons are named for their physical locations within the digestive tract, 
and corresponding to the direction food takes as it encounters those sections. Within 
these parts of the colon, contractions from smooth muscle groups work food material 
back and forth to move waste through the colon and eventually, out of the body. The 
intestinal walls secrete alkaline mucus for lubricating the colon walls to ensure 
continued movement of the waste. The ascending colon travels up along the right side 
of the body. Due to waste being forced upwards, the muscular contractions working 
against gravity are essential to keep the system running smoothly. The next section of 
the colon is termed the transverse colon due to it running across the body horizontally. 
Then, the descending colon turns downward and becomes the sigmoid colon, 
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followed by the rectum and anus. The ileocecal valve is located where the small and 
large intestines meet. This valve is an opening between the small intestine and large 
intestine allowing contents to be transferred to the colon. The cecum follows this 
valve and is an opening to the large intestine. The rectum is essentially a storage place 
for waste and is the final stop before elimination occurs. When elastic receptors 
within the rectum are stimulated, these nerves signal that defecation needs to occur. 
 The anus is the last portion of the colon, and is a specialized opening bound with 
elastic membranes, sensitive tissues, and muscles and nerves allowing it to stretch for 
removing bowel movements of varying sizes.  
 
 
 
 
Fig: 3 Anatomy of the Colon  
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Advantages of colon specific drug delivery 
• A near neutral pH, a much longer transit time and a much greater responsiveness 
to absorption enhancers. 
• Reducing the adverse effects in the treatment of colonic diseases (ulcerative 
colitis, colorectal cancer, crohn’s disease etc.) 
• By producing the ‘friendlier’ environment for peptides and proteins when 
compared to upper gastrointestinal tract. 
• Minimizing extensive first pass metabolism of steroids. 
• Preventing the gastric irritation produced by oral administration of NSAIDS.  
• Targeting the drug required in amoebiasis to the colon. 
• Delayed release of drugs to treat angina, asthma and rheumatoid arthritis. 
Limitations of colon specific drug delivery 
• The location at the distal portion of the alimentary canal, the colon is difficult to  
access. 
• Successful delivery requires the drug to be in solution before it arrives in the 
colon, but the fluid content in the colon is lower and more viscous than in upper 
GIT, which is the limiting factor for poorly soluble drugs. 
• Lower surface area and relative tightness of the tight junctions in the colon can 
restrict drug transport across the mucosa in to the systemic circulation.2 
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1.4 COATING 
1.4.1 Enteric coating8:                 
An enteric coating is a barrier applied to oral medication that controls the 
location in the digestive system where it is absorbed. Enteric refers that the drug 
releases in to the small intestine. Most enteric coatings work by presenting a surface 
that is stable at the highly acidic pH found in the stomach, but breaks down rapidly at 
a less acidic (relatively more basic) pH. For example, they will not dissolve in the 
acidic juices. 
Acidic pH (pH ~3) in stomach, Alkaline pH (above pH 7-9) environment 
present in the small intestine. Drugs which have an irritant effect on the stomach can 
be coated with a substance that will only dissolve in the small intestine. For such 
types of drugs, enteric coating added to the formulation tends to avoid the stomach's 
acidic exposure, delivering them instead to a basic pH environment (intestine's pH 5.5 
and above) where they do not degrade, and give their desired action .Recently, some 
companies have begun to utilize enteric coatings on fish oil (omega 3 fatty acids) 
supplements.  
                 
Fig.4 Highly Acidic Gastric secretion pH 1-4      Fig.5 Duodenum pH 6.8 
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Reasons for enteric coating: 
• To protect acid-liable drugs from the gastric fluid 
• To protect gastric distress or nausea due to irritation from drug 
• To deliver drugs intended for local action in the intestines. 
• To deliver drug that are optimally absorbed in the small intestine to their 
primary absorption site in their most concentrated form.  
• To provide a delayed release component to repeat actions. 
• Protect the drugs from harmful effect of the gastric contents; some of the 
drugs are prone to be hydrolyzed in acid media. 
 
COMPOSITIONS OF COATING 
•  Cellulose acetate phthalate (cap) 
• Methyl Acrylate-Methacrylic acid copolymers  
• Cellulose acetate succinate  
• Hydroxy propyl methyl cellulose phthalate  
• Hydroxy propyl methyl cellulose acetate succinate  
• Polyvinyl Acetate Phthalate (PVAP)  
• Methyl Methacrylate Methacrylic acid copolymers  
• Sodium alginate and Stearic acid 
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Advantages of Coating:  
1. High productivity /faster coating High film adhesion-produces much better tablet 
finish with improved tablet gloss.  
2. Easy processing, Low requirement of energy  
3. Improvement in efficiency of other production operations e.g. packaging of tablets 
on high speed packaging machines.  
4. Environmental friendly system-eliminates the use of organic solvents.  
5. Low cost. 
1.4.2 Sugar-Coating  
Compressed tablets may be coated with colored or uncolored sugar layer. The coating 
is water soluble and quickly dissolves after swallowing. The sugar coat protects the 
enclosed drug from the environment and provides a barrier to objectionable taste or 
odour. The sugar coat also enhances the appearance of the compressed tablet and 
permit imprinting manufacturing’s information. Sugar coating provides a combination 
of insulation, taste masking, smoothing the tablet core, coloring and modified release. 
The disadvantages of sugar coating are the time and expertise required in the coating 
process and thus increases size, weight and shipping costs. 
• Sugar coating process involves five steps 
I. Sealing/Water proofing:  Provides a moisture barrier and harden the tablet 
surface. 
II.  Sub-coating:  Causes a rapid buildup to round off the tablet edges. 
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III. Grossing/Smoothing: Smoothes out the sub-coated surface and increases the 
tablet size to predetermine dimension. 
IV.      Coloring: Gives the tablet its color and finished size. 
V.       Polishing: Produces the characteristics gloss. 
 
 
I. Sealing/Water proofing. 
  
Prior to applying any sugar/water syrup, the tablet cores must be sealed, thoroughly 
dried and free of all residual solvents.  The seal coat provides a moisture barrier and 
hardness to the surface of the tablet in order to minimize attritional effects. Core 
tablets having very rapid disintegration rates conceivably could start the disintegration 
process during the initial phase of sugar coating. The sealants are generally water-
insoluble polymers/film formers applied from an organic solvent solution. The 
quantities of material applied as a sealing coat will depend primarily on the tablet 
porosity, since highly porous tablets will tend to soak up the first application of 
solution, thus preventing it from spreading uniformly across the surface of every 
tablet in the batch. Hence, one or more further application of resin solution may be 
required to ensure that the tablet cores are sealed effectively.  
 
Common materials used as a sealant include Shellac, Zinc, Cellulose acetate phthalate 
(CAP), Polyvinyl acetate phthalate, Hydroxyl propyl cellulose, Hydroxy propyl 
methylcellulose etc. 
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II. Sub-coating: 
 
Sub-coating is the actual start of the sugar coating process and provides the rapid 
buildup necessary to round up the tablet edge. It also acts as the foundation for the 
smoothing and color coats. 
 
• Generally two methods are used for sub-coating: 
 
i.  The application of gum based solution followed by dusting with powder and 
then drying. This routine is repeated until the desired shape is achieved. 
ii.  The application of a suspension of dry powder in gum/sucrose solution 
followed by drying. 
  
Thus sub-coating is a sandwich of alternate layer of gum and powder. It is necessary 
to remove the bulk of the water after each application of coating syrup. 
 
 
 
  Table No. 1 - Typical Binder Solution Formulation for Sub-coating  
 
Materials %W/W %W/W 
Gelatin 6 3.3 
Gum acacia (powdered) 8 8.7 
Sucrose (powdered) 45 55.3 
Distilled water To 100ml To 100ml 
 
 
Table No. 2 - Typical Dusting Powder Formulation for Sub-coating  
  
Materials  %W/W %W/W 
Calcium carbonate  40.0 - 
Titanium dioxide 5.0 1.0 
Talc, asbestos free 25.0 61.0 
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Sucrose(powdered ) 28.0 38.6 
Gum acacia (powdered) 2.0 - 
 
 
III. Grossing/ smoothing: 
 
The grossing/smoothing process is specifically for smoothing and filing the 
irregularity on the surface generated during sub-coating. It also increases the tablet 
size to a predetermined dimension. 
 
If the sub-coating is rough with high amount of irregularities then the use of grossing 
syrup containing suspended solids will provide more rapid buildup and better filling 
qualities. Smoothing usually can be accomplished by the application of a simple syrup 
solution  
 
(Approximately 60-70 % sugar solid). This syrup generally contains pigments, starch, 
gelatin, acacia or opacifier if required. Small quantities of color suspension can be 
applied to impart a tint of the desired color when there are irregularities in coating. 
  
IV. Color coating: 
 
This stage is often critical in the successful completion of a sugar coating process and 
involves the multiple application of syrup solution (60-70 % sugar solid) containing 
the requisite coloring matter. Mainly soluble dyes were used in the sugar coating to 
achieve the desired color, since the soluble dye will migrate to the surface during 
drying. But now a day the insoluble certified lakes have virtually replaced the soluble 
dyes in pharmaceutical tablet coating. The most efficient process for color coating 
involves the use of a pre-dispersed opacified lake suspension.  
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V.  Polishing 
 
Sugar-coated tablets needs to be polished to achieve a final elegance. Polishing is 
achieved by applying the mixture of waxes like beeswax, Carnauba wax, candelila 
wax or hard paraffin wax to tablets in polishing pan. 
 
1.5 SCIENTIFIC PRINCIPLES OF STABILITY TESTING9-13 
 
The purpose of stability testing is to provide evidence on how the quality of a drug 
substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity and light. Therefore, stability 
studies provide data to justify the storage condition and shelf-life of the drug product. 
For drug substance, such studies establish the retest date in addition to the storage 
condition of raw material. 
 
Stability of a drug substance or drug product during drug synthesis, formulation, and 
storage must be ascertained. Instability could lead to chemical degradation and loss of 
drug potency and the possible formation of new chemical species with potential toxic 
side effects. Therefore, early evaluation of a drug substance should include 
elucidation of stability under a number of environmental conditions. To aid in the 
prediction of drug stability, forced or accelerated degradation is performed to 
elucidate potential degradation products, determine their safety, and develop 
analytical procedures to quantitate these new chemical species. These forced 
degradation studies may be predictive of the degradation pathways of the drug under 
normal conditions. In fact, information learned from studying the kinetics of 
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degradation may be used to extrapolate rates of degradation which might apply during 
normal storage conditions and could be utilized to predict long-term stability under 
these normal storage conditions. 
 
The development of appropriate analytical methods will then aid in the development 
of purification schemes to remove degradants and to allow the development of drug 
impurity profiles which will be used for setting purity specifications and for defining 
the drug which is to be utilized in pre-clinical animal and later human studies. 
 
The analytical procedures to assess stability must encompass the elements common to 
validating analytical assays. The methods must be validated according to the 
parameters of accuracy, precision, robustness and specificity, limits of detection and 
quantitation, linearity of active ingredient assays, degradants, and other reaction 
products.  
 
These stability studies will expose the drug to potentially degrading conditions 
including moisture, oxygen, pH, temperature, and light. Discovery that a drug has a 
very restricted stability range will affect process and packaging development, and 
labeling for long-term shelf-life.  
 
Sensitivity to such environmental factors may also dictate the necessity for inclusion 
of stabilizers in the formulation and will dictate the choice of dosage form and 
packaging. It may turn out that such restricted stability and associated developmental 
costs to remedy the situation will be sufficient to eliminate a potentially viable drug 
product. For products which are expected to be sold and used worldwide, attention 
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must be given to differing climate zones when considering expiry dating and long-
term stability. 
 
For solid dosage forms, the solubility, efficacy, and stability of a drug may depend on 
the particular crystalline state of the drug. Many crystalline drugs can exist in 
different crystalline states called polymorphs. It is expected that characterization of 
the solid dosage forms include not only the chemical identity but the polymorphic 
distribution as well. The polymorphic content may be characterized by techniques 
such as x-ray powder diffraction, Raman and infrared spectroscopy. The sensitivity to 
environmental conditions of different polymorphs of the same drug entity may differ 
and therefore polymorphic composition may play an important role in determining a 
drug’s stability. 
 
Once the drug sensitivities are determined and the product development process 
addresses these issues and defines the product, then the long-term official stability 
studies may begin. The conditions and protocols for these studies are well defined by 
FDA and ICH guidelines 
 
Requirements of stability program 
Written program must include: 
_ Sample size and test intervals, 
_ Storage conditions for samples, 
_ Reliable, meaningful, and specific test methods, 
_ Testing of drug product in marketed container, 
_ Testing of drug product for reconstitution at dispensing time and reconstituted time. 
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2.0. AIM, OBJECTIVE AND PLAN OF WORK 
The aim and objective of the present study was to formulate and evaluate delayed 
release dosage form of local acting agent i.e., Stimulant laxative. 
2.1 OBJECTIVE:  
• To formulate the various prototype formulation trials and evaluate. 
• To optimize the formulation with reference product by using different 
manufacturing techniques to observe the process variation. 
• To carry out Drug-Excipient compatibility studies. 
• To evaluate and compare the properties of developed pharmaceutically test 
product with reference product by uniformity of drug content and related 
substance. 
• To evaluate and match the disintegration time of the reference product in different 
phosphate buffer. 
• To carry out stability studies of developed product as per ICH guidelines. 
2.2 SCOPE: 
Stimulant laxative used for the treatment of constipation and bowel evacuation. It acts 
mainly in the large intestine following oral administration. 
Bisacodyl was recently subjected to carcinogenicity testing and was shown to be free 
of carcinogenic/ mutagenic potential and therefore, from a safety perspective is the 
stimulant laxative of choice. 
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However Bisacodyl (API) is directly irritant to the intestinal mucosa of the upper 
intestine and can cause griping and epigastric pain. To reduce the incidence of such 
effects drug is conventionally administered as enteric- coated tablets. Enteric-coated 
formulations are suitable vehicles to modify the release of active substances such that 
release at specific target areas within the GI tract can be affected. 
A major aim of enteric coating is protection of drugs that are sensitive or unstable at 
acidic pH. This is particularly important for drugs such as enzymes and proteins, 
because these macromolecules are rapidly hydrolyzed and inactivated in acidic 
medium. 
The advantage of sugar coating is to protect the enclosed drug from the environment 
and provide a barrier to objectionable taste or odour. It also enhances the appearance 
of the compressed tablet and permit imprinting manufacturing information. 
2.3. PLAN OF WORK 
2.3.1 PREFORMULATION  STUDY 
a) DRUG EXCIPIENT COMPATIBILITY STUDIES. 
b) EVALUATION OF PRE-COMPRESSION PARAMETERS 
• Angle of repose 
• Bulk density and tapped density 
• Compressibility index 
• Particle size distribution. 
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2.3.2 FORMULATION DESIGN 
               Preparation of delayed release tablets using different techniques 
• Direct compression  
2.3.3 EVALUATION OF DELAYED RELEASE TABLETS 
• Weight variation  
• Thickness 
• Hardness 
• Friability 
• Disintegration test 
• Dissolution 
• Drug content estimation 
• Related substance. 
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3.0. LITERATURE REVIEW 
3.1 GASTRO-RESISTANT TABLET  
 
Patel Gayatri C.*, et al14: 
 
Enteric coatings are pH sensitive and can be considered as a pulsatile drug delivery 
system because of the lag time is essential for the drugs that undergo degradation in 
gastric acidic medium which irritate the gastric mucosa. The present study explores 
the comparative utility of the enteropolymers (enteric-coated polymers) such as 
acrycoat L-100, acrycoat S-100, ethyl cellulose (EC) and cellulose acetate phthalate 
(CAP) in developing a suitable dosage form, exhibiting a minimum drug release in the 
upper regions of the gastrointestinal tract (GIT) on order to provide site specificity as 
well as time controlled formulation. Core tablets of diclofenac sodium (DS) were 
prepared by wet granulation and coated with one of the coating polymers to a varying 
coating level. From the dissolution data obtained, it was found that the dissolution rate 
was inversely proportional and lag time was directly proportional to the coating level 
applied. Comparative dissolution data revealed that, of all the various polymers at 
varying coating level used, a 15% acrycoat S 100 and EC was most suitable for 
pulsatile drug delivery. Moreover, such study also provides a site specific drug 
delivery. 
 
Anroop B Nair*,et al15: 
The present study was an attempt to formulate and evaluate enteric coated tablets for 
esomeprazole magnesium trihydrate. Different core tablets were prepared and 
formulation (F-1) was selected for further enteric coating, based on the disintegration 
time. Seal coating was applied to achieve 3% weight gain using opadry®. Enteric 
coating was carried out using different polymers like Eudragit L-30 D-55, hydroxy 
propyl methylcellulose phthalate, cellulose acetate phthalate and Acryl-EZE® to 
achieve 5% weight gain. Disintegration studies showed that the formulations failed in 
0.1 N HCl media. Hence the quantity of enteric coating was increased to 8% w/w. In 
vitro analysis of the developed tablets was carried out. Results from disintegration 
time and dissolution rate studies indicate that all the esomeprazole enteric tablets 
prepared possess good integrity, desirable for enteric coated tablets. Among the 
polymers studied, the methacrylic polymers exhibited better dissolution rate than the 
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cellulose polymers. Stability studies indicate that the prepared formulations were 
stable for a period of three months. This study concluded that enteric coated tablets of 
esomeprazole can be prepared using any of the enteric coating polymer studied using 
a minimal weight gain of 8%. 
 
Vishal V. Rajguru*,et al16: 
 
Colonic drug delivery has gained increased importance not just for the delivery of the 
drugs for the treatment of local diseases associated with the colon but also for its 
potential for the delivery of proteins and therapeutic peptides.  Formulation coated 
with enteric polymers releases drug, when pH move towards alkaline range while as 
the multicoated formulation passes the stomach, the drug is released after a lag time 
of 3-5 hours that is equivalent to small intestinal transit time. Drug coated with a 
bioadhesive polymer that selectively provides adhesion to the colonic mucosa may 
release drug in the colon. The review is aimed at understanding Pharmaceutical 
approaches to colon targeted drug delivery systems for better therapeutic action 
without compromising on drug degradation or its low bioavailability. 
 
Sateesh kumar et al17: 
Oral administration of different dosage forms is the most commonly used method due 
to greater flexibility in design of dosage form and high patient acceptance, but the 
GIT presents several formidable barriers to drug delivery. Colon specific drug 
delivery has gained increased importance not just for the delivery of the drugs for the 
treatment of local diseases associated with the colon but also for its potential for the 
delivery of proteins and therapeutic peptides. 
 
  Literature Review 
Department of Pharmaceutics, R.V.S. College of Pharmaceutical Science 
 
24
Sharma Anuj et al18:  
Although oral delivery has a become a widely accepted route of administration of 
therapeutic drugs, the GIT presents several formidable barrier to drug delivery. The 
delivery of drugs to the colon has a number of therapeutic implications in the field of 
drug delivery. In the recent times, the colon specific drug delivery system is also 
gaining importance not only for local drug delivery of drugs but also for the systemic 
delivery of protein and peptide drugs. The  various approaches that can be exploited 
to target the release of drug to the colon including prodrug  formation, coating with 
PH sensitive polymer, coating with biodegradable polymers, embedding in 
biodegradable matrices, hydrogel time release system, osmotic and bio-adhesive for 
achieving colon specific drug delivery. 
Dinesh Kaushik et al19: 
Oral or non parental drug delivery systems are widely used for the administration of 
therapeutic drugs. However, the gastro intestinal tract present several barriers to anti 
cancer drugs in targeting colon cancer. Colonic drug delivery has  gained  increased 
importance not just for the delivery of  the drugs for the treatment of local disease 
associated with the colon but also for its potential for the delivery of proteins and 
therapeutic peptides. To achieve successful colonic delivery, which is considered to 
be the optimum site for colon-targeted delivery of drugs, colon targeting is of prime 
importance for the topical treatment of disease of colon such as chorn’s diseases, 
ulcerative colitis, colorectal cancer, and amebiasis. 
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Kerl G.wagner et al20:  
 
 Enteric coated bisacodyl pellets were compressed in to divisible disintegrating tablets 
on a high speed rotary tablet press and investigated for pellet damages. The degree of 
pellet damages was examined via the bisacodyl dissolution during the acid treatment 
of the drug release test for enteric coated articles according to USP 23. The damages 
depended on the type of filler-binder used and the settings of the press. Avicel PH 101 
proved to be the most suitable filler-binder, effecting homogenous distribution of the 
pellet. 
  
Ohno, shigeru et al21: 
 
Enteric coatings are provided on a solid pharmaceutical dosage forms by a method 
comprising covering the dosage form with an aqueous solution of a polymeric 
substance having carboxyl groups in the water soluble salt form and contacting the 
thus coated dosage forms with an inorganic acid to convert the polymeric substance in 
to the water-insoluble acid form. The coating solution includes no organic solvent, 
and this method is safe. 
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3.2 REVIEW OF LITERATURE ON EUDRAGIT POLYMERS 
 
 
                    
 Many pharmaceutical dosage forms irritate the stomach mucosa due to their chemical 
properties. Others undergo chemical changes in gastric acid and through the action of 
enzymes, thus becoming less effective. In order to protect the stomach from irritation 
and/or to protect drugs from degradation in gastric acid /enzymes, enteric coated 
dosage forms are regularly formulated. The Eudragit grades for enteric coatings are 
based on anionic polymers of methacrylic acid and methacrylates. They contain –
COOH as a functional group. They dissolve at ranges from pH5.5 to7.The different 
products are available as aqueous dispersions, powders and organic solvents. 
Table No. 3. Eudragit polymers with different dissolution properties: 
Applications Eudragit 
Grades 
Availability Functionality Dissolution 
Properties 
Drug delivery in 
Duodenum 
EUDRAGIT 
L100-55 
Powder 
Anionic 
polymers with 
Methacrylic 
Acid as a 
functional 
group 
Dissolution above 
pH 5.5 EUDRAGIT 
L30D-55 
Aqueous 
dispersion 30%  
Drug delivery in 
Jejunum 
EUDRAGIT 
L100 
Powder Dissolution above 
pH 6.0 
Drug delivery in 
Ileum 
EUDRAGIT 
S100 
Powder Dissolution above 
pH 7.0 
Colon delivery EUDRAGIT 
FS30D 
Aqueous 
dispersion 30% 
Dissolution above 
pH 7.0 
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Ceballos A et al22: 
 
Extended-release theophylline (TP) matrix tablets were prepared by direct 
compression of drug and different pH-dependent (Eudragit L100, S100 and L100-55) 
and pH-independent (Eudragit RLPO and RSPO) polymer combinations. The 
influence of varying the polymer/polymer (w/w) ratio and the drug incorporation 
method (simple blend or solid dispersion) was also evaluated. Drug release, 
monitored using the Through Flow Cell system, markedly depended on both the kind 
of Eudragit polymer combinations used and their relative content in the matrix. 
Maintaining a constant 1:1 (w/w) drug/polymers ratio, the selection of appropriate 
mixtures of pH-dependent and pH-independent polymers enabled achievement of a 
suitable control of TP release. In particular, matrices with a 0.7:0.3 w/w mixture of 
Eudragit L100-Eudragit RLPO showed highly reproducible drug release profiles, with 
an almost zero-order kinetic and allowed 100% released drug after 360 min. As for 
the effect of the drug incorporation method, simple blending was better than the solid 
dispersion technique, which not only did not improve the release data reproducibility, 
but also caused, unexpectedly, a marked slowing down in drug release rate.                        
 
 
Guo HX et al23:  
     
The enteric-coated dosage forms are designed to resist the acidic environment of the 
stomach and to disintegrate in the higher pH environment of the intestinal fluid. 
Polymers for enteric coating can be applied to solid dosage forms (granules, pellets, 
or tablets) from aqueous latex or pseudo latex dispersions, aqueous solutions of alkali 
salts, or organic solvent solutions.                                                               
 
M.Zahirul I Khan et al24: 
 
Lactose-based placebo tablets were coated using various combinations of two 
methacrylic acid copolymers, Eudragit® L100-55 and Eudragit® S100, by spraying 
from aqueous systems. The Eudragit® L100-55–Eudragit® S100 combinations (w/w) 
studied were 1:0, 4:1, 3:2, 1:1, 2:3, 1:4, 1:5 and 0:1. The coated tablets were tested in 
vitro for their suitability for pH dependent colon targeted oral drug delivery. The same 
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coating formulations were then applied on tablets containing mesalazine as a model 
drug and evaluated for in vitro dissolution rates under various conditions. The results 
also demonstrated that a combination of Eudragit® L100-55 and Eudragit® S100 can 
be successfully used from aqueous system to coat tablets for colon targeted delivery 
of drugs and the formulation can be adjusted to deliver drug at any other desirable site 
of the intestinal region of the GI tract on the basis of pH variability. For colon 
targeted delivery of drugs the proposed combination system is superior to tablets 
coated with either Eudragit® L100-55 or Eudragit® S100 alone. 
 
Poonam Kushwaha et al25:         
 
In the recent year colonic drug delivery has gained importance for delivery of drug for 
the treatment of local diseases associated with colon and systemic delivery of 
therapeutic peptides and proteins. This article gives an overview on anatomy and 
physiology of the colon and approaches utilized for colon specific drug delivery. This 
article also discusses advantages and limitations of the approaches applied and work 
has been done in the field of site specific drug delivery to colon. 
Xue Duan et al26: 
 
Layered double hydroxides (LDHs) or so-called anionic clays consist of cationic 
brucite-like layers and exchangeable interlayer anions. Because of their 
biocompatibility, these layered inorganic solids can be used as host materials to create 
drug–LDH host–guest supramolecular structures. Because of the basicity of LDHs 
however, LDHs as drug delivery system will be limited for use in the stomach where 
pH is 1.2. A core-shell material has been prepared therefore in this work. A non-
steroidal anti-inflammatory drug, Fenbufen-intercalated LDHs as the core was coated 
with enteric polymers, Eudragit® S 100 or Eudragit® L 100 as a shell, giving a 
composite material which shows controlled release of the drug under in vitro 
conditions which model the passage of a material through the gastrointestinal tract. 
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Davis et al27: 
 
The subject invention involves pharmaceutical compositions in dosage unit form, for 
peroral administration of bisacodyl to a human or lower animal having a 
gastrointestinal tract, with a lumen there through, with a small intestine and a colon 
with a junction there between, comprising: 
(a) A safe and effective amount of rapidly-dissolving bisacodyl means; and 
(b) A delivery means which prevents the release of bisacodyl from the dosage 
form into the lumen of the gastrointestinal tract during transport of the dosage 
form through the lumen until the dosage form is near the junction between the 
small intestine and the colon and which then releases the bisacodyl in the 
lumen near the junction between the small intestine and the colon. 
Hiroto Bando et al28: 
 
Theophylline was found to dissolve completely from pellets coated with Eudragit® 
S100:L100 (1:1) plasticized with 50% TEC at pH 6.0 after 2 h. The shape of the 
pellets was maintained during dissolution testing. In conclusion, the plasticizer 
content in the film coating influenced the dissolution profile of theophylline from 
pellets coated with Eudragit® S100:L100 (1:1). A large amount of the TEC was 
leached from the enteric films before drug release was initiated and a TEC level of 
approximately 30% in the films, based on the polymer weight, was the critical amount 
of TEC for initiating drug release during dissolution testing at pH 6.0. While enteric 
films are more soluble and dissolve faster at higher pH values, the kinetics of 
plasticizer release was one of the important factors controlling the dissolution of drugs 
at pH 6.0, at which pH the enteric polymers were insoluble. 
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Zeitoun,paul et al29: 
  
Coated compress tablets for oral administration are disclosed which substantially 
disintegrate specially at the level of the colon. The tablets comprise a compressed 
center piece containing an active agent which center piece is coated by a first coating 
layer which is comprised of a mixture of pharmaceutically acceptable film forming 
organic polymer materials which is non-deteriorated by a neutral or a alkaline 
aqueous medium and a second coating layer which is comprised of pharmaceutically 
acceptable Enteric organic polymer coating material. 
 
Allwood,Michael  et al30: 
 
Delayed release compositions comprising an active compound and glassy amylose. A 
variety of different types of active compound may be employed in the compositions. 
The compositions are particularly adapted for achieving the selective release of 
medicaments in to the colon. 
 
 
Iamartino et al31: 
 
Orally administrable pharmaceutical preparation containing an active ingredient to be 
released in the lower part of the gastrointestinal tract, i.e., in the large intestine and 
especially colon, consisting of a core containing a therapeutically active substance and 
coated with three protection later of different solubility. 
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Gary Robert et al32:   
                                
The present invention relates to a pharmaceutical composition in a unit dosage form 
for peroral  administration in a human or lower animal, having a gastrointestinal tract 
comprising a small intestine and a colon with a lumen there through having an inlet to 
the colon from the small intestine, comprising; 
 
a. A safe and effective amount of rapidly dissolving Bisacodyl incorporated into 
compressed, bi-convex tablets. 
b. A non-PH dependent smoothing coat applied to the tablet  to provide  a  
smooth tablet surface  free from edges and sharp curves; and 
c. An enteric polymer coating material comprising at least one inner coating  
layer  and  only one outer coating  layer; where  in the rapidly dissolving 
Bisacodyl is released at a point near the inlet to, or within the colon; each of 
the inner coating  layer(s) is an enteric polymer that begins to dissolve in an 
aqueous media at a PH between about 5 to about 6.3; and the outer coating 
layers is an enteric polymer that begins to dissolve in an aqueous media at  a 
pH between about 6.8 to about 7.2  
 
John T.Fell et al33: 
The effect of a pH-dependent polymer coating, Eudragit S100 on its ability to 
protect a model drug and control its release from rapidly disintegrating tablets has 
been examined Invitro conditions were chosen to mimic those likely to occur during 
transit from the mouth to the colon. Dissolution was affected by coating thickness and 
pH. At a given pH, the nature of the buffer system dramatically affected dissolution 
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and disintegration profiling experiments involving PH changes and mimicking the 
extremes of conditions prevailing in vivo indicated that release of drug may 
commence in the duodenum or not at all. 
 
Jain D, Panda AK et al34: 
 
He investigates the Eudragit S100 entrapped insulin microspheres for oral delivery. 
They were found that insulin loaded Eudragit S100 microspheres retard the release of 
insulin at low pH. And release insulin at pH 7.4 in the colon. 
 
Kelm et al32: 
 
The present invention relates to a pharmaceutical composition in a unit dosage form 
for peroral administration in a human or lower animal, having a gastrointestinal tract 
comprising a small intestine and a colon  with a lumen there through having an inlet 
to the colon from the small intestine, comprising: 
a. A safe and effective amount of rapidly dissolving Bisacodyl incorporated in to 
or coated on the surface of a dosage form selected from the group consisting 
of a spherical substrate, an elliptical substrate, a hard capsule, or a compressed 
tablet, with a maximum diameter of about 3mm to about  10mm;and 
b. An enteric polymer coating material. 
The enteric polymer coating material has a coating thickness of at least about 250 
micrometers. 
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4.0. DRUG PROFILE35-36           
Description: The drug is the derivatives of diphenylmethane, are stimulant laxatives 
used to treat constipation. It is administered either orally as a tablet or rectally as an 
enema or rectal suppository.  
Chemical Name:  4, 4- (prydinyl-2-methylene) diphenyl diacetate. 
   
Molecular Structure: 
 
 
 
(pyridin-2-ylmethanediyl)dibenzene-4,1-diyl diacetate 
                          OR 
4,4'-(pyridin-2-ylmethylene)bis(4,1-phenylene) diacetate 
 
Molecular formula:  C22H19NO4. 
Molecular weight: 361.4. 
CAS NO:  603-50-9. 
Description: A white or almost white crystalline powder. 
Solubility: Practically insoluble in water, soluble in acetone, sparingly soluble in 
alcohol. It dissolves in dilute mineral acids. 
pH:  6-7 (10%w/v suspension in water) 
Melting point: 131-1350c 
 
Loss on Drying: 0.18 %w/w. 
Mechanism of Action: Stimulant laxatives are believed to produce laxation by 
directly stimulating peristaltic movement of the intestine via local mucosal irritation, 
thus increasing motility. More recent studies suggest that stimulant laxative (drug) 
promotes evacuation of the colon by altering intestinal fluid and electrolyte 
absorption. This causes a net intestinal fluid accumulation and produces laxation.  
Pharmacokinetics: Drug is administered either orally or rectally. Drug is minimally 
absorbed (15%), and the onset of action of the drug begins 6-8 hours after an oral 
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dose and 15- 60 minutes after rectal administration. Drug distributes locally, and the 
circulating drug undergoes hepatic metabolism and is then excreted in the urine.  
                                              Pharmacokinetic Data 
             Bioavailability 15% 
              Metabolism Hepatic(CYP450-mediated) 
               Half life 16 Hours 
               Excretion Primarily in the feces, systemically 
absorbed  drug is excreted in the 
urine 
 
CONTRAINDICATIONS/PRECAUTIONS: 
All laxatives are contraindicated in patients with appendicitis, GI obstruction, 
abdominal conditions requiring surgery, or undiagnosed abdominal pain.  
Stimulant laxatives, such as drug (API) are most likely to cause GI irritation, fluid and 
electrolyte loss, nausea, vomiting, or diarrhea.  
Laxative dependence can occur with long-term or excessive laxative therapy.  
Drug administration can exacerbate ulcerative colitis, rectal fissures, ulcerative 
lesions of the colon, and fecal impaction. Therefore, the drug is contraindicated in 
patients with these conditions.  
Prolonged Drug therapy can cause potassium depletion.  
The safety of Drug usage during pregnancy has not been determined, so use of the 
drug should be avoided in women of child bearing age or during pregnancy, unless 
the potential benefits outweigh the risks.  
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DRUG INTERACTIONS: Concomitant use of Drug as oral tablets and antacids, 
milk, or other drugs that cause an increase in gastric pH levels can cause the enteric 
coating of the drug to dissolve prematurely, leading to possible gastric or intestinal 
irritation.  
ADVERSE REACTIONS: Stimulant laxatives, such as Drug (API) are   most likely 
to cause GI irritation, fluid and electrolyte loss, or diarrhea. Short-term usage (at 
normal dosages) typically results in abdominal pain or cramps, faintness, 
nausea/vomiting, or mild abdominal discomfort.  
• Prolonged usage of drug can cause hypokalemia.   
• Prolonged use of stimulant laxatives can result in dependence, leading to 
constipation when use is interrupted. 
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5. 0 EXCIPIENTS PROFILE
37
 
5.1. LIST OF API AND EXCIPIENTS USED: 
 
S. No. MATERIALS SUPPLIERS CATEGORY 
1 Bisacodyl API Dhisman 
pharmaceuticals 
Drug 
2 Lactose monohydrate 
(tabletose100) 
Meggle excipient & 
Technology 
Diluent 
3 Microcrystalline Cellulose 
(AVICEL PH101) 
FMC Biopolymer Adsorbent; 
suspending agent 
4 Klucel LF hydroxyl propyl 
cellulose 
Aqualon Coating agent; 
viscosity-increasing 
Agent 
5 Maize starch B 5% Roquttee Binder/Disintegrant 
6 Pregelatinized starch 
(Lycatab) 
Roquttee Binder 
7 HPMC E5 Dow chemicals Film coating 
8 Eudragit L100 Evonik Enteric coating 
polymer 
9 Eudragit S100 Evonik Enteric coating 
polymer 
10 TEC Vertillus performance 
materials Inc 
Plasticizer 
11 Magnesium Stearate Ferro-Portugal Lubricant 
12 Sucrose MB Sugars & pharma Sweetening & Bulking 
agent 
13 HPMC E15 Dow chemicals Film coating 
14 Purified talc Luzenac pharma Glidant 
15 Iron oxide yellow Roha Dye Chem Coloring agent 
16 IPA Merck Non aqueous solvent 
17 Titanium dioxide Krons-Germany Opacifier 
18 Carnauba  wax Quality Chemical 
industries, Mumbai 
Polishing agent 
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5.2. Lactose Monohydrate 
Nonproprietary 
names 
 
Lactose (BP), Lactose Monohydrate (PhEUR, USP-NF). 
Synonym CapsuLac, GranuLac, Lactochem, lactosum monohydricum, 
onohydrate, Pharmatose, PrismaLac, SacheLac, SorboLac, 
pheroLac, SuperTab 30GR, Tablettose. 
 
Chemical Name and 
CAS Registry Number 
O-b-D-Galactopyranosyl-(1!4)-a-D-glucopyranose 
monohydrate, [10039-26-6] 
 
Empirical Formula 
and molecular weight 
1. Formula: C12H22O11·H2O.  2. 
2. MW: 360.31 
Description In solid state, lactose appears as various isomeric forms, 
depending on the crystallization and drying conditions, i.e. 
α-lactose monohydrate, β-lactose anhydrous and α-lactose 
anhydrous. Lactose occurs as white to off-white crystalline 
particles or powder, it is odorless and slightly sweet-
tasting. 
Structural formula 
 
 
pH 5.5-8.9.(1%w/w aqueous solution at 25o) 
Solubility Insoluble in chloroform, ethanol, ether. Soluble in water 
in ratio of 1 in 5 
Melting point 201–2020C (for dehydrated a-lactose monohydrate) 
Moisture content Lactose monohydrate contains normally has a range of 
4.5–5.5% w/w water content. 
Functional Category Dry powder inhaler carrier, lyophilization aid, tablet binder, 
tablet and capsule diluent, tablet and capsule filler. 
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Applications in 
Pharmaceutical 
formulation or 
technology 
Lactose is widely used as a filler and diluent in tablets and 
capsules. Lactose is also used as a diluent in dry-powder 
inhalation. Lactose is added to freeze-dried solutions to 
increase plug size and aid cohesion. Lactose is also used in 
combination with sucrose to prepare sugar-coating 
solutions. It may also be used in intravenous injections. 
Lactose is also used in the manufacture of dry powder 
formulations for use as aqueous film-coating solutions or 
suspensions. Direct-compression grades of lactose 
monohydrate are available as spray-dried lactose and 
anhydrous lactose. 
 
Incompatibilities A Maillard-type condensation reaction is likely to occur 
between lactose and compounds with a primary amine 
group to form brown, or yellow-brown-colored products. 
Lactose is also incompatible with amino acids, amfetamines 
and lisinopril. 
 
Stability and storage 
conditions 
Mold growth may occur under humid conditions (80% 
relative humidity and above). Lactose may develop a 
brown coloration on storage, the reaction being accelerated 
by warm, damp conditions. Solutions show mutarotation. 
Lactose should be stored in a well-closed container in a 
cool, dry place. 
 
Safety Lactose is widely used as a filler and filler-binder in orals 
and injections. Adverse reactions to lactose are largely 
attributed to lactose intolerance, results in lactose being 
undigested and may lead to cramps, diarrhea, distension, 
and flatulence            
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5.3 Microcrystalline cellulose (Avicel PH101) 
  
Synonyms Avicel PH; Celex; cellulose gel; Celphere; Ceolus KG; 
crystalline cellulose; E460; Emcocel ; Ethispheres; 
Fibrocel; Pharmacel; Tabulose; Vivapur. 
Description Microcrystalline cellulose is purified, partially 
depolymerized cellulose that occurs as a white, odorless, 
tasteless, crystalline powder composed of porous particles. 
It is commercially available in different particle sizes and 
moisture grades that have different properties and 
applications. 
Functional 
categories 
Adsorbent; suspending agent; tablet and capsule diluent; 
tablet disintegrant. 
Solubility Slightly soluble in 5% w/v sodium hydroxide solution; 
practically insoluble in water, dilute acids, and most 
organic solvents. 
pH 5.0–7.5 
Density (bulk)  
Density (tapped) 
0.32 g/cm3 
0.45 g/cm3 
Stability and storage 
conditions 
Microcrystalline cellulose is a stable though hygroscopic 
material. The bulk material should be stored in a well-
closed container in a cool, dry place. 
Incompatibilities Microcrystalline cellulose is incompatible with strong 
oxidizing agents. 
Safety 
 
 
Microcrystalline cellulose is widely used in oral 
pharmaceutical formulations and food products and is 
generally regarded as a relatively nontoxic and nonirritant 
material. Microcrystalline cellulose is not absorbed 
systemically following oral administration and thus has 
little toxic potential. Consumption of large quantities of 
cellulose may have a laxative effect, although this is 
unlikely to be a problem when cellulose is used as an 
excipient in pharmaceutical formulations. 
Applications Microcrystalline cellulose is widely used in pharmaceuticals, 
primarily as a binder/diluent in oral tablet and capsule 
formulations where it is used in both wet-granulation and 
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direct-compression processes. In addition to its use as a 
binder/diluent, microcrystalline cellulose also has some 
lubricant and disintegrant properties that make it useful in 
tableting. 
 
 
5.4 Hydroxy propyl cellulose Klucel KF 
 
Synonyms Cellulose, hydroxypropyl ether; E463; hyprolose; Klucel; 
Methocel; Nisso HPC; oxypropylated cellulose. 
Description Hydroxypropyl cellulose is a white to slightly yellow-
colored, odorless and tasteless powder 
Functional 
categories 
Coating agent; emulsifying agent; stabilizing agent; 
suspending agent; tablet binder; thickening agent; 
viscosity-increasing agent. 
Solubility soluble 1 in 10 parts dichloromethane; 1 in 2.5 parts 
ethanol (95%); 1 in 2 parts methanol; 1 in 5 parts propan-
2- ol; 1 in 5 parts propylene glycol; and 1 in 2 parts water. 
Practically insoluble in aliphatic hydrocarbons; aromatic 
hydrocarbons; carbon tetrachloride; petroleum distillates; 
glycerin; and oils. 
pH 5.0–8.5 for a 1%w/v aqueous solution. 
Density (bulk)  0.5 g/cm3 
Stability and storage 
conditions 
Hydroxypropyl cellulose powder is a stable material, 
although it is hygroscopic after drying. Aqueous solutions 
of hydroxypropyl cellulose are stable at pH 6.0–8.0, with 
the viscosity of solutions being relatively unaffected. 
However, at low pH aqueous solutions may undergo acid 
hydrolysis, resulting in chain scission and hence a decrease 
in solution viscosity. Ultraviolet light will also degrade 
hydroxypropyl cellulose and aqueous solutions may 
therefore decrease slightly in viscosity if exposed to light 
for several months. 
Aqueous hydroxypropyl cellulose solutions have optimum 
stability when the pH is maintained at 6.0–8.0, and also 
when the solution is protected from light, heat, and the 
action of microorganisms. 
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Hydroxypropyl cellulose powder should be stored in a well 
closed 
container in a cool, dry place. 
Incompatibilities Hydroxypropyl cellulose in solution demonstrates some 
incompatibility with substituted phenol derivatives, such as 
methylparaben and propylparaben. The presence of anionic 
polymers may increase the viscosity of hydroxypropyl 
cellulose solutions. The compatibility of hydroxypropyl 
cellulose with inorganic salts varies depending upon the 
salt and its concentration 
 
Safety 
 
 
Hydroxypropyl cellulose is widely used as an excipient in 
oral and topical pharmaceutical formulations. It is also 
used extensively in cosmetics and food products. 
Hydroxypropyl cellulose is generally regarded as an 
essentially nontoxic and nonirritant material. However, the 
use of hydroxypropyl cellulose as a solid ocular insert has 
been associated with rare reports of discomfort or 
irritation, including hypersensitivity and edema of the 
eyelids. Adverse reactions to hydroxypropyl cellulose are 
rare.  
Applications Hydroxypropyl cellulose is widely used in oral and topical 
pharmaceutical formulations. In oral products, 
hydroxypropyl cellulose is primarily used in tableting as a 
binder, film-coating, and extended-release matrix former. 
Concentrations of hydroxypropyl cellulose of 2–6% w/w 
may be used as a binder in either wet-granulation or dry, 
direct-compression tableting processes. Concentrations of 
15–35% w/w of hydroxypropyl cellulose may be used to 
produce tablets with an extended drug release. The release 
rate of a drug increases with decreasing viscosity of 
hydroxypropyl cellulose. Hydroxypropyl cellulose is also 
used in cosmetics and in food products as an emulsifier 
and stabilizer. 
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5.5. Maize Starch:   
Synonyms Amido, amidon, amilo, amylum. 
Description It is as an odorless & tasteless, fine, white color powder 
comprising very small spherical/ovoid granules whose size 
&   shape are characteristic for each botanical variety.  
Functional 
categories 
Glidant, tablet & capsule diluent, tablet & capsule 
disintegrant, tablet binder. 
Solubility Practically insoluble in cold ethanol (95%) & in cold water.   
pH 5.5-6.5   
Density (bulk)  
Density (tapped) 
0.462 g/cm3    
0.658 g/cm3    
Stability and storage 
conditions 
Dry, unheated starch is stable if protect from high 
humidity. When use as diluent/disintegrant in solid dosage 
form, starch is consider to be inert under normal storage 
condition. However , heated starch solution/past are 
physically unstable & readily attacked by microorganism to 
form a wide verity of starch derivatives & modified starch 
that have unique physical properties. Starch should store in 
airtight container in & dry place. 
Incompatibilities _ 
Safety 
 
 
Starch is widely used as excipient in pharmaceutical 
formulations, particularly oral tablet. It is inedible food 
substance & generally regarded as a nontoxic and 
nonirritant material. However, oral consumption of massive 
doses can be harmful owing the formation of starch calculi, 
which cause bowel obstruction. 
Applications It is an excipient primarily in oral solid dosage formulations 
where it is utilized as a binder, diluent & disintegrant. As a 
diluent, starch is use for preparation of standardized 
triturates colorants or blending process in manufacturing 
operations. it is use as disintegrant at concentration of 3-
15%w/w. unmodified starch does not compress well and 
tends to increase the tablet friability and capping  in high 
concentration. 
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5.6. Pregelatinized starch                                   
Nonproprietary Names BP: Pregelatinized starch 
PhEur: Amylum pregelificatum 
UspNF: Pregelatinized starch. 
Synonyms Compressible starch, Instastarch, Lycatab, Merigel, 
Lycatab PGS; 
Chemical Name and 
CAS Registry Number 
PG [9005-25-8] 
Emperical formula and 
molecular weight 
(C6H10O5)n  where n= 300-1000 
Functional category Tablet and capsule diluent; Tablet binder; tablet and 
capsule disintegrant; 
Description Pregelatinized starch occurs as a moderately coarse to 
fine, white to off-white colored powder. It is odorless 
and has a slight characteristic taste. 
Typical properties 
Angle of repose 40.7 
Density(bulk).(tapped) 0.586g/cm3 (0.879g/cm3) 
Density(true) 1.516g/cm3 
Flow ability 18-23%. 
Solubility Practically insoluble in organic solvents slightly soluble in 
cold water, depending up on the degree of  
Pregelatinization. 
 
Safety 
 
Pregelatinized starch and starch are widely used in oral 
solid dosage formulations. PG starch is generally 
regarded as a non toxic and non irritant excipient. 
However, oral  
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Consumption of large amount of PG starch may be 
harmful. 
 
Stability and storage 
conditions 
PG starch is stable but hygroscopic material, which 
should be stored in a well-closed container in a cool, dry 
place. 
Applications PG starch is a modified starch used in oral capsule and 
tablet formulations as a binder, diluent, disintegrant. In 
comparison to starch grades of PG starch may be 
produced with enhanced flow and compression 
characteristics such that the PG material may be used as 
a tablet binder in dry compression or direct compression 
processes. In such process, PG starch is self-lubricating 
 
5.7. Sucrose: 
 
Nonproprietary Names BP: Sucrose. 
JP: Sucrose. 
PhEur: Saccharum 
USPNF:  Sucrose 
Synonyms: Beet Sugar, Cane sugar,  Saccharose, Sugar. 
Chemical Name and CAS 
Registry Number 
Beta-D-fructofuranosyl-alpha-D-
glucopryanoside[57-50-1] 
Emperical Formula and 
molecular weight 
C12H22O11    342.30 
Functional category Coating agent, granulating agent, tablet 
binder, tablet filler, and tablet-capsule diluent. 
Description Sucrose occurs as colorless crystals, as 
crystalline masses or blocks or as a white 
crystalline powder; it is odorless and  has a 
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sweet taste 
Typical properties 
Bulk density 0.60g/cm3. 
Tapped density 0.82g/cm3. 
True density 1.6g/cm3 
Flowability Crystalline sucrose is free flowing, where as 
powdered sucrose is a cohesive solid. 
Stability and Storage conditions Sucrose has good stability at room 
temperature and at moderate relative 
humidity. It absorbs up to 1% moisture, which 
is released up on heating at 90oC. 
Safety Sucrose  is hydrolyzed  in the small intestine 
by the enzyme sucrase to yield dextrose and 
fructose, which are then absorbed when 
administered intravenously, sucrose is 
excreted  unchanged in the urine 
 
Applications Sucrose is widely used in oral pharmaceutical 
formulations. Tablets that contain large 
amounts of sucrose may harden to give poor 
disintegration. Sucrose syrups are used as 
tablet coating  agents  at concentration 
between 50% and 67%w/w. 
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5.8. Carnauba wax: 
 
Nonproprietary Name BP: Carnauba wax 
 JP:  Carnauba wax. 
 PhEur:  Cera carnauba. 
 USPNF: Carnauba wax. 
Synonyms Brazil wax ; Caranda wax ; E903 
Chemical Name and CAS 
Registry Number  
Carnauba wax [8015-86-9] 
Functional  Category Coloring agent 
Description It occurs as a light brown to pale yellow 
colored powder, flakes, or irregular lumps of a 
hard brittle wax. It has a characteristic bland 
odor and practically no taste. 
Solubility Soluble in warm chloroform and in warm 
toluene; slightly soluble in boiling  ethanol 
(95%); practically insoluble in water 
Safety Carnauba wax is widely used in oral 
pharmaceutical formulations, cosmetics, and 
certain food products. It is generally regarded 
as an essentially non-toxic and non-irritant 
material. 
Stability and storage conditions Carnauba wax is stable and should be stored 
in a well-closed container, in a cool, dry 
place. 
Applications: Carnauba wax is widely used in cosmetics, 
certain foods and pharmaceutical 
formulations. It is the hardest and highest 
melting of the waxes commonly used in the 
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pharmaceutical formulation and is used 
primarily as a 10% w/v aqueous emulsion to 
polish sugar coated tablets. The carnauba 
wax coating produces tablets of good luster 
without rubbing. Carnauba wax may also be 
used in powder form to polish sugar coated 
tablet 
 
5.9. Talc: 
 
Synonyms Hydrous magnesium calcium silicate, hydrous magnesium 
silicate, talcum, Luzenac Pharma, magnesium hydrogen 
metasilicate, purtalc, superiore. 
Description Very fine, white to grayish-white, odorless, impalpable, 
unctuous, crystalline powder. It adheres readily to the skin 
and is soft to the touch and free from grittiness. 
Functional 
categories 
Anti-caking agent, glidant, tablet and capsule Diluent, tablet 
and capsule lubricant. 
Solubility Practically insoluble in dilute acids and alkalis, organic 
solvents, and water.  
Ph 7-10 (20% w/v aqueous dispersion) 
Stability and 
storage conditions 
Talc is a stable material and may be sterilized by heating at 
160°C for not less than 1 hour. Should be stored in well closed 
container in a cool and dry place. 
Incompatibilities Incompatible with quaternary ammonium compound. 
Safety Talc is not adsorbed systematically following oral injection and 
therefore regarded as an essentially nontoxic material. 
Applications Anti-cocking agent, glidant, tablet and capsule Diluent, tablet 
and capsule lubricant 
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5.10. Titanium Dioxide: 
 
Synonyms Anatase titanium dioxide, brookite titanium dioxide, color 
index number 77891, E1701, rutile titanium dioxide.  
Description White, amorphous, odorless and tasteless non hygroscopic 
powder. Titanium dioxide may occur in several different 
crystalline for: rutile, anatase and brookite.   
Functional 
Categories 
Coating agent, pigment and opacifier. 
Solubility Practically insoluble in dilute sulfuric acid, hydrochloric 
acid, nitric acid, organic solvent and water. Soluble in 
hydrofluoric acid and hot conc. sulfuric acid. 
Stability and 
storage conditions 
Titanium dioxide is extremely stable at high temperature 
due to the strong bond between the tetravalent titanium 
ion and the bivalent oxygen ions. 
Stored in a well closed container, protect from light, in a 
cool, dry place. 
Incompatibilities Titanium dioxide may interact with certain active 
substances. it has also been shown to induce photo 
oxidation of unsaturated lipids. 
Safety Titanium dioxide is widely used in foods and oral and 
topical pharmaceutical formulations. It is generally 
regarded as essentially nonirritant and nontoxic excipient. 
Applications Titanium dioxide is widely used in confectionary, cosmetics, 
foods, and topical and oral pharmaceutical formulation as a 
white pigment. Titanium dioxide is also used in 
dermatological preparations and cosmetics such as 
sunscreens.  
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5.11. Eudragit 
Synonyms Eastacryl 30D, Eudragit, Kollioat, Polymeric methacryl 
Description Polymethacrylates  are the cationic and anionic 
polymers of the methacrylic acids  
Eudragit E:- Cationic polymer, soluble in gastric  fluid 
upto pH=5 
Eudragit L, S: - Anionic copolymer of methacrylic acid 
and methyl methacrylate 
Eudragit L:-Carboxyl group : Ester group = 1:1 
Eudragit S:- Carboxyl group : Ester group = 1:2 
White free flowing powders, resistant to gastric media 
soluble in intestinal fluid pH 6 – 7 
Eudragit RL,RS = Ammonio methacrylate copolymer 
Methacrylate with amine like odour 
Functional categories Film former, tablet binder, tablet diluents 
Loss on drying 50% 
Stability and storage 
conditions 
Dry powder stable at temperature less than 300 C 
Dispersions sensitive to extreme temperature and 
phase separation occurs below 00C 
Incompatibilities Coagulation may occur by soluble electrolytes, organic 
solvents and extreme temperature 
Applications It is used as enteric coating film former resistant to 
gastric juice and dissolves readily above pH 5.5 
                                 
5.12. Hydroxy propyl methyl cellulose    
Nonproprietary Names Hypromellose (BP, JP, PhEur, USP) 
Synonyms Benecel, hydroxypropyl methylcellulose, HPMC, 
hypromellosum,    Methocel,    methylcellulose propylene 
glycol ether, methyl hydroxypropylcellulose, Metolose, 
pharmacoat. 
Chemical Name              Cellulose hydroxypropyl methyl ether 
Empirical Formula     Hypromellose as a partly O-methylated and O-(2-
hydroxypropylated)  cellulose. 
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Molecular weight 10000–1500000 
Structural Formula 
 
 
Description 
 
Hypromellose is an odorless and tasteless, white or 
creamy-white fibrous or granular powder 
Typical Properties 
pH  5.0–8.0 (2% w/w solution)   
Loss on drying 45.0%  
Residue on ignition     41.5% 
Density  1. Density (bulk) 0.341 g/cm3. 
2. Density (tapped) 0.557 g/cm3. 
3. Density (true) 1.326 g/cm3. 
Melting point 190–2000C 
Moisture content      Hypromellose absorbs moisture from the atmosphere; the 
amount of water absorbed depends upon the initial 
moisture content and the temperature and relative 
humidity of the surrounding air. 
Solubility Soluble in cold water, practically insoluble in hot water, 
chloroform, ethanol (95%), and ether, but soluble in 
mixtures of ethanol and dichloromethane, mixtures of 
methanol and dichloromethane  and mixtures of water 
and alcohol.  
Specific gravity 1.26  
Nominal viscosity 
(mPas) 
3 - 100000 (2%w/w solution at 20oC) 
The different commercial grades are available with varying 
in viscosities, 
Methocel K4M             4000 mPas 
Methocel K15M 15000 mPas 
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Methocel K100M 100000 mPas 
Functional Category 
 
Bioadhesive material; coating agent; controlled-release 
agent; emulsifying agent; extended-release agent; film-
forming agent; modified-release agent; solubilizing agent; 
suspending agent; sustained-release agent; tablet binder; 
thickening agent. 
 
Applications in 
Pharmaceutical 
Formulation or 
Technology 
 
Hypromellose is widely used in oral, ophthalmic, nasal, 
and topical pharmaceutical formulations. Concentrations 
between 2% and 5% w/w may be used as a binder in 
either wet- or dry-granulation processes. High-viscosity 
grades may be used to retard the release of drugs from a 
matrix at levels of 10–80% w/w in tablets and capsules. 
Depending upon the viscosity grade, concentrations of 2–
20% w/w are used for film-forming solutions to film-coat 
tablets. Hypromellose at concentrations between 0.45–
1.0% w/w may be added as a thickening agent to vehicles 
for eye drops and artificial tear solutions. It is also used 
commercially in liquid nasal formulations at a 
concentration of 0.1%. It is also widely used in cosmetics 
and food products. 
 
Stability and Storage 
Conditions 
It is a stable material, although it is hygroscopic after 
drying. It should be stored in a well-closed container, in a 
cool, dry place. 
 
Incompatibilities 
 
It is incompatible with some oxidizing agents. Since it is 
nonionic, hypromellose will not complex with metallic salts 
or ionic organics to form insoluble precipitates. 
 
Safety 
 
It is generally regarded as a nontoxic and nonirritating 
material, although excessive oral consumption may have 
a laxative effect. 
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5.13. Magnesium Stearate 
 
Nonproprietary names Magnesium Stearate (BP, USP-NF, PhEUR). 
Synonym Dibasic magnesium stearate, magnesium distearate, 
magnesium octadecanoate, octadecanoic acid, magnesium 
salt, stearic acid. 
 
Chemical Name and 
CAS Registry Number 
Octadecanoic acid magnesium salt, [557-04-0]. 
Empirical Formula and 
molecular weight 
Formula: C36H70MgO4. MW: 591.24. Structural formula: 
[CH3(CH2)16COO]2Mg 
Description Magnesium stearate is a very fine, light white, precipitated 
or milled poorly flowing, cohesive powder, impalpable 
powder of low bulk density, having a faint odor of stearic 
acid and a characteristic taste. The powder is greasy to 
the touch and readily adheres to the skin 
Solubility Practically insoluble in ethanol, ether and water, slightly 
soluble in warm benzene and warm ethanol (95%).  
Melting point 117–1500C. 
Functional Category Tablet and capsule lubricant. 
Applications in 
Pharmaceutical 
formulation or 
technology 
Magnesium stearate is widely used in cosmetics, foods, 
and pharmaceutical formulations. It is primarily used as a 
lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. It is also 
used in barrier creams. 
Incompatibilities Incompatible with strong acids, alkalis, and iron salts. 
Avoid mixing with strong oxidizing materials. Magnesium 
stearate cannot be used in products containing aspirin, 
some vitamins, and most alkaloidal salts.  
Stability and storage 
conditions 
Magnesium stearate is stable and should be stored in a 
well-closed container in a cool, dry place.  
Safety Magnesium stearate is non-toxic for oral administration 
and larger consumption may result in laxative effect and 
mucosal irritation.  
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5.14. Iron oxide yellow: 
 
  Synonyms Iron oxide yellow, hydrated ferric oxide, yellow ferric 
oxide, mapico yellow; 
Chemical Name and 
CAS Registry Number 
Iron oxide yellow monohydrate [51274-00-1] 
 
Emperical Formula 
and molecular 
weight 
1. Formula-   Fe2O3.H2O 
2. Mol Wt.-    177.70   
Functional Category  Colorants 
Description Iron oxides occur as yellow, red, black or brown powder. 
The color depends on the particle size and shape, and the 
amount of combined water. 
Stability and storage 
conditions 
Iron oxides should be stored in well-closed containers 
stored in  a cool, dry place 
Incompatibilities Iron oxides have been reported to make hard gelatin 
capsules brittle at high temperatures when the residual 
moisture is 11-12%. This factor affects the use of iron 
oxides for coloring hard gelatin capsules, and will limit the 
amount that can be incorporated in to gelatin material 
Safety  Iron oxides are widely used in cosmetic, foods and oral 
and topical pharmaceutical applications. They are 
generally regarded as non-toxic and non-irritant excipients 
Applications Iron oxides are widely used in cosmetics food and 
pharmaceutical  applications as colorants and UV 
absorbers 
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5.15. Isopropyl Alcohol: 
 
Nonproprietary Names BP: Isopropyl Alcohol 
JP: Isopropanol 
PhEur: Isopropyl Alcohol 
USP: Isopropyl Alcohol 
Synonyms Alcohol isopropylicus; dimethyl carbinol; IPA; 
isopropanol; petrohol; 2-propanol; sec-propyl 
alcohol; rubbing alcohol. 
Description Isopropyl alcohol is a clear, colorless, mobile, 
volatile, flammable liquid with a characteristic, 
spirituous odor resembling that of a mixture of 
ethanol and acetone; it has a slightly bitter taste. 
Empirical Formula & 
Molecular Weight 
Formula - C3H8O  
MW - 60.1 
Solubility 
Solubility Miscible with benzene, chloroform, 
ethanol (95%), ether, glycerin, and water. 
Soluble in acetone; insoluble in salt solutions. 
Forms an azeotrope with water, containing 87.4% 
w/w isopropyl alcohol (boiling point 80.378C). 
Functional category 
Disinfectant; solvent. 
Auto ignition temperature 
42.5°C 
Dielectric constant D20 = 
18.62 
D20 = 18.62 
Boiling point 
82.4°C 
Stability and storage 
conditions 
Isopropyl alcohol should be stored in an airtight 
container in a cool, dry place. 
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Incompatibilities With oxidizing agents such as hydrogen peroxide 
and nitric acid, which cause decomposition. 
Isopropyl alcohol may be salted out from aqueous 
mixtures by the addition of sodium chloride, 
sodium sulfate, and other salts, or by the addition 
of sodium hydroxide 
Safety LD50 (dog, oral): 4.80 g/kg(9) 
LD50 (mouse, oral): 3.6 g/kg  
LD50 (mouse, IP): 4.48 g/kg 
LD50 (mouse, IV): 1.51 g/kg 
LD50 (rabbit, oral): 6.41 g/kg 
LD50 (rabbit, skin): 12.8 g/kg  
LD50 (rat, IP): 2.74 g/kg. 
Applications Used in cosmetics and pharmaceutical 
formulations, primarily as a solvent in topical 
formulations. It is not recommended for oral use 
owing to its toxicity. 
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6.0 EXPERIMENTAL WORK 
 
6.1. EQUIPMENTS USED 
Table No.4 List of Equipments 
Sr. No. Name of instrument Manufacturing Company 
1  Digital weighing balance Essae digi DS-450SS  
2  Common weighing balance Essae Teraoka Ltd 
3  Stirrer REMI motors Ltd 
4  Neocota Kevin 
5   Compression Machine 27 station Cadmach 
6  Blender 2 liters Gansons 
7  Sieves(ASTM) Jayant Scientific Ltd 
8  Heating Mantle SUNBIM  
9  Vernier Calipers Mitutoyo corp 
10  Hardness tester Benchsaver series VK200 
11 Disintegration test apparatus Electro lab 
12 Friabilator Electro lab EF2 
13 Moisture  Analyser  Essae MB45 
14  Digital pH meter  Mettler Toledo 
15 Bulk density apparatus Campbell  electronics 
16  HPLC  Agilent Technologies.1200 series 
 
 
 
6.2 INNOVATOR PRODUCT CHARACTERISATION :  
Innovator product is characterized for its various parameters as 
follows: 
 
• Manufactured by: Boehringer Ingelheim Limited, France. 
• Batch Number: 18973. 
• Expiry date: June 2013. 
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• Dosage form: Tablets. 
• Coated/uncoated: coated, Enteric coated, Sugar coated. 
• Embossing:  upper punch –None, Lower punch—None. 
• Color: yellow Colored. 
• Shape: Biconvex   Shaped (round). 
• Diameter (mm) Initial: 5.92, 5.82, 5.96, 5.89, 5.88, 6.03. 
• After DT in 0.1N HCl for 2hrs: 5.58, 5.64, 5.59, 5.55, 5.68, 5.56. 
• Thickness (mm) Initial: 3.63, 3.51, 3.55, 3.59, 3.50, 3.62. 
• After DT in 0.1NHCl for 2hrs: 3.18, 3.27, 3.10, 3.04 3.15, 3.20. 
• Hardness(N):  41—51 
• Weight Initial (mg):100.7, 95.7, 101.2, 99.7, 101.0, 96.7. 
• After DT in 0.1NHCL for 2hrs: 77.3, 74.5, 77.6, 75.8, 79.4, 73.5. 
9 Disintegration Time(min’ sec’’); 
• After DT in 0.1NHCL for 2hrs:  In pH 6.4 up to 2hrs the tablet was not 
disintegrating. In pH 7.6 -33mins was taken to disintegrate the tablets. 
• Pack:  Blister pack. 
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• Storage: Do not store above 250C 
6.3. PREFORMULATION STUDIES38 
Preformulation testing is an investigation of physical and chemical properties of a drug 
substance alone and when combined with excipients. It is the first step in the rational 
development of dosage forms. 
Preformulation studies relate to pharmaceutical and analytical investigation carried out-
processing and supporting formulation development efforts of the dosage form of the 
drug substance preformulation yields basic knowledge necessary to develop suitable 
formulation for toxicological use. It gives information needed to define the nature of the 
drug substances and provide a dosage form. Hence, the following preformulation studies 
were performed for the obtained sample of drug. (Leon Lachman et. al.)   
6.3.1.Organoleptics properties: 
 a)  Color: A small quantity of Bisacodyl powder was taken in butter paper and viewed in 
well-illuminated place. 
  b) Taste and Odor: Very less quantity of Bisacodyl Aspirin powder was used to get 
taste with the help of tongue as well as smelled to get the odor.    
  
6.3.2. Physical Characteristics:  
a)  Loss on drying: This is employed in IP, BP, and USP. Although the loss in weight 
in the samples so tested, principally is due to water, small amount of other volatile 
material will contribute to the weight loss the moisture balance combines both the 
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drying presses and weight recording, it is suitable where large numbers of sample are 
handled and where a continuous record of loss in weight with time is required. 
Procedure: 
Placed about 1gm of API in the plate of digital moisture balance instrument. Set the temp 
105oC and run up to constant weight finally read out the percentage loss on drying 
automatically. 
% LOD = loss on drying/total sample × 100 
 b)  Angle of repose:  In this method weighed 20gm of bulk powder, passed it through 
sieve no 40 mesh size .Then allowed to flow under gravity though funnel and angle of 
incline of the formed. By measuring the height and having a fixed base i.e. diameter.   Put 
the value into following formula;   
Angle of Repose Ə = tan –1 h/r 
 
tan Ө= h/r 
 
Where 
 h =   height of peak 
 r =   radius of peak base 
 
          Table No. 5 - Angle of repose. 
 
Angle of repose (degrees) Flow ability 
25-30 Excellent 
31-35 Good 
36-45 Passable 
>46 Very Poor 
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c)  Determination of Density:  
Bulk Density:  
 Determined by pouring bulk drug pre sieved by 40 mesh size in to a graduated, cylinder 
via large funnel in and measuring the volume and weighed.  The tapped density is 
determined by placing a graduated cylinder containing a known   mass of drug or 
formulation on a mechanical tapper apparatus USP 1. This is operated for a fixed 100 
taps. The powder bed volume has reached minimum. 
Then quantities put in formula:     
Bulk density:  Bulk mass / Bulk volume 
True density:   Bulk mass / tapped volume 
d)  Compressibility index:  
It is determined by taking tapped density and bulk density which has been put in the 
formula given below and determined compressibility index using following formula. 
 
100 X 
density Tapped
densitybulk  -density  Tapped index  ility Compressib =  
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 Table No. 6 - Compressibility index limits 
%  Compressibility Flowability 
5-12 
12-16 
 
18-21 
 
23-25 
 
33-38 
 
More than  40 
Excellent 
Good 
 
Fair 
 
Poor 
 
Very poor 
 
Very, very poor 
  
d. Hausner Ratio:   It is the ratio of tapped volume or tapped density to bulk density. 
                               
                                              Hausner Ratio = Vb/ Vt   
 
Table No. 7 - Hausner Ratio index limits: 
                Hausner  Ratio                  Flowability 
                      1.2-1.3                              
                      1.3-1.4                     
                      1.4-1.5 
                       1.6-1.9 
              Excellent                              
                   Good 
 
                  
                    Fair 
 
 
                     Poor 
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e. Particle Size:  Sieving method 
The particle size distribution and shapes affect various chemicals and physical properties 
of drug substance. The effect is not only on the physical properties of solid drug but also, 
in some instances, on their biopharmaceutical behavior. E.g. the bioavailability of 
griseofulvin and phenacetin is directly related to the particle size distribution of these 
drugs. 
Size also plays a role on the homogeneity of the final tablet size can also be a factor in the 
stability, fine materials are relatively and are open to attack from the diluents and active 
raw materials several tools are commonly employed to monitor the size for quantities 
particle size distribution analysis of material that range upward from about 50mm, sieving 
or screening is appropriate. Most pharmaceutical powders, however, range in size from 1 
to 120 μm. 
In the sieving process the powder is passed over a preferred screen, so that particle 
sufficiently small will pass through, while those that are over size will be retained on the 
sieve. Sieve is therefore, a simple ‘go/no go’ test which divides the powder into fraction 
above and below a specified size. 
Method: 
This test was performed with the help of sieve of different size. They were fitted in the 
platform of sieve shaker in such a way that the coarse sieve was placed on top 
corresponding to the finer sieves. Placed 10 gm of the Drug X on top and run the machine 
to separate out the powder and after some time off the machine and took the weight of the 
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powder remained on the sieve (s) finally, calculated the % of powder retained on each 
sieve by the following equation.  
                                   Amount of powder retained  
           % Powder retained = ----------------------------------- X 100 
                                                                 10 
6.3.3. Solution Properties 
a)  Solubility:  
Solubility measured by shaking an excessive previously weighed solid solute in the 
presence of the solvent, in sealed container at a temperature i.e. 250C. After equilibration 
a sample is withdrawn. After each addition, the system is vigorously shaken and 
examined visually for any undissolved solute particles. The solubility is expressed in 
turns of ratio of solute and solvent. 
b)  pH:  
Weighed and transferred accurately about 1.0g of sample in a 20 ml clean and dried 
volumetric flask, dissolved in carbon dioxide free water and made up the volume to 20 ml 
with same solvent, mixed. Determined the pH of freshly prepared solubility by using 
precalibrated pH meter. 
c)  Melting Point: -  
It is one of the parameters to judge the purity of crude drugs. In case of pure chemicals or 
phytochemicals, melting points are very Sharp and constant. Since the crude drug 
contains the mixed chemicals, they are described with certain range of melting points. 
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6.3.4. Identification of Drug and compatibility study: 
In the tablet dosage form the drug is in intimate contact with one or more excipients; the 
latter could affect the stability of the drug. Knowledge of drug-excipient interactions is 
therefore very useful to the formulator in selecting appropriate excipients. This 
information may already be in existence for known drugs. For new drugs or new 
excipients, the preformulation scientist must generate the needed information. 
Drug-Excipient Compatibility studies 
 Procedure:  
• Taken weighed quantity of drug and excipients according to ratio given in 
literature.  
• Poured drug in individual vials. 
• Then drug plus individual excipient poured in to separate vials according ratio. 
Labeled every vial.   
• Finally keep all vials at 250 C/60%R.H and 500C/75% R.H for 1 Month. 
• Before keeping vials for exposure initial appearance of powder mixture were 
noted down. Then sealed the vials with rubber closure.  
• After 1 month vials were removed from exposure and observed for physical 
appearance only.   
• Results are mentioned in result and discussion. 
 The blend of the active pharmaceutical ingredient and excipients were subjected to 
accelerated conditions of temperature and humidity viz. 25ºC / 60% RH, 50ºC / 75% RH 
and refrigeration 4 - 8ºC. As per ICH guidelines to evaluate the compatibility by 
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observing, the physical parameters of the physical mix with a view to narrow down on the 
probable excipients to be used.   
 
The evaluation was carried out for 4 weeks and the samples from 25ºC and 60% RH, 
50ºC and 75% RH incubation chambers were observed for any physical change such as 
Colour, odour etc. by comparing with samples stored in refrigeration 4 - 8ºC. 
 
The API was compatible with the excipients tested. The ingredients identified for 
developing Bisacodyl was limited to generally regarded as safe commonly used 
excipients viz.: - Lactose Monohydrate,  Pregelatinized Starch, Magnesium state, Talc, 
Sucrose, HPMC E15, MCC105, Mannitol, Eudragit L100, Eudragit S100, TEC  
                
During the development, trials were conducted by varying the ratios of the excipients in 
the blend to optimize the formula by measuring the physical characteristics such as 
average weight, hardness, friability and thickness. 
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 6.4. FORMULATION TABLES: 
Experimental work: Delayed Release Tablets 
6.4.1. Formula for core tablet 
Batch no: F1 – F5 
                                              Table No 8.  Formula for core tablet 
Sr. 
No. Ingredients 
Amount (mg/ per tablet) 
Formulation No. 
F1 F2 F3 F4 F5 
1 API 5 5 5 5 5 
2 Lactose 
Monohydrate 
40.1 35.1 35.1 35.1 25 
3 Maize Starch 3.0 5.0 8.3 8.3 - 
4 Pre gelatinized 
starch 
0.5 3.5 1.5 1.5 19.9 
5 Magnesium 
Stearate 
1.4 1.4 0.1 0.1 0.1 
 Total 50.00 50.00 50.00 50.00 50.00 
 Conclusion Check 
Feasibility 
Properties 
Capping 
was 
observed 
Unity of 
drug 
content 
was not 
in limit 
Unity of 
drug 
content 
was not in 
limit 
Core tablet 
was 
optimized 
 
According to above trials the F-5 was the optimized formula for the core tablet. It 
complies all the parameters for core tablet.  
So this formulation was selected further study. Selected formulation was taken for seal 
coating with HPMC 5cps as seal coating polymer and enteric coating with Eudragit S100 
and Eudragit L100 as enteric coating polymer.  
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Preparation of Core Tablets (direct compression): 
Step I: Shifting - the weighed quantity of API, Lactose monohydrate, maize starch, PG 
Starch sieved through 40# size.  
Step II:  Blending   
             The above shifted materials were mixed using 2ltr blender for 10min. 
Step III: Lubrication  
Finally the above shifted materials were lubricated with Magnesium Stearate for 3 
min in octagonal blender.  These blended materials were ready for compression. 
Step IV:  Compression of blend material:  
• Compression machine parameter: (for core tablet) 
Table No 9. Compression machine parameter 
Punch       5 mm deep concave shape 
Machine  27 Station B tooling 
Relative 
Humidity 
50 % 
Temperature 27 % 
 
• Tablet parameters:-  
 Table No 10. Tablet parameters 
Weight of core tablet  50.0 mg  
Diameter 5±0.2mm 
Thickness 2.3±0.2mm    
Hardness NLT 2 kp  
Friability NMT 1.0% 
Disintegration  NMT 15 min in  distilled water at 
±37oC 
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6.4.2. Seal Coating:  
 
Seal coating layer is done to protect drug and for increasing the stability of a drug. 
Mechanical strength of tablets also increased. In order to prevent interaction between 
active drug & enteric coating solution, the seal coating solution made up of cellulose 
derivatives. Hydroxyl propyl methyl cellulose polymer used for seal coating. 
a) Application of separating layer  
1. Separating layer is done to protect drug and for increasing the stability of a drug. 
2. Moisture protection 
3. Good storage stability 
4. Improved passage of the dosage form  
5. Smooth and glossy surfaces 
6. Prevent interaction between active drug & enteric coating solution. 
b)  Procedure for preparation of seal coating solution:  
1.  Dispensed all the ingredients as per manufacturing formula. 
2. Then take purified water & dissolved HPMC-5 cps for continuous stirring to  45 
min. 
3.   Finally, above solution can be filter through #100 & use for spraying.                                                  
c)  Seal Coating Parameters: 
Table No 11. Seal Coating Parameters 
Coating pan RPM 8 to 16 
Atomization Pressure  Less than 1.8 Kg / cm2 
Inlet Air Temperature  40° to 55o C 
  Experimental Work 
Department of Pharmaceutics, R.V.S. College of Pharmaceutical Science 
 
69
Spray RPM 3 to 10 
Spray  Gun 0.8 mm nozzle 
Exhaust Temperature 42 to 50 
                                                         
d) Formulation for seal coating: 
Batch no: F5A 
                                        Table No 12.   Formulation for seal coating 
Sr. 
No. 
Ingredients Formulation No.  
F5A 
1. Weight of  uncoated tablets 50mg 
2. H.P.M.C.-5cps 7.5mg 
3. Purified Water Q.S 
4. % w/w Subcoating solution 5% 
5. Theoretical weight of tablets 57.5mg 
6. Practical weight of tablets 57.8mg 
7 %  Build up 15% 
 Conclusion Seal coating was optimized. 
 
After giving seal coat on core tablet to all formulation. It was decided to give enteric coat 
on the same tablets. For this the enteric coating polymer Methacrylic acid co-polymer was 
selected. Initially 9 %  was selected randomly as initial concentration for enteric coating 
.After spraying coating solution on tablet bed determined required parameters. The 
increased polymer concentration  was increased until the required parameters for enteric 
coating tablet was obtained. 
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6.4.3. Enteric Coating solution preparation39: 
 
a) Procedure for Enteric coating solution 
1. Dispense all the required quantity of ingredients as per manufacturing formula. 
2.  Dispense total quantity of solvent (IPA + water) and mix it properly. 
3. To 50% of solvent, add talc &TEC slowly later mix it for 10-15min with high 
shear. 
4.  Take another 50% of solvent & add EudragitS100, EudragitL100 slowly under 
stirring condition in another Stainless Steel vessel & Stir it up to completly 
dissolve in 45-60min. 
5.    Add Talc &TEC solution to the Eudragit solution &mix it for 10min & spray the 
solution with suitable parameters. 
b) Enteric Coating Parameters: 
Table No 13. Enteric Coating Parameters 
Coating pan RPM 8to 16 
Inlet Air Temp 30° to 35° C 
Exhaust temperature 32° to 34oC 
Spray  Gun 0.8 mm nozzle 
Spray RPM 3to5 
Atomization Pressure 1 to 1.5kg/ cm2 
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c) Enteric Coating- Batch no: F5B to F5G                             
Table No 14. Enteric coating Formulation 
Sr. 
No. 
 
Ingredients 
Formulation No. 
F5B F5C F5D F5E F5F F5G 
1 Initial Weight 
of Tablets Bead  
57.5mg 57.8mg 57.6mg 57.4mg 57.5mg 57.7mg 
2 Eudragit L100 0.89mg 0.99mg 1.09mg 1.19mg 1.29mg 1.48mg 
3 Eudragit S100 2.94mg 3.27mg 3.59mg 3.92mg 4.25mg 4.90mg 
4 TEC 0.58mg 0.64mg 0.71mg 0.77mg 0.84mg 0.97mg 
5 Talc 0.77mg 0.86mg 0.94mg 1.03mg 1.11mg 1.28mg 
6 Purified Water  Q.S Q.S Q.S Q.S Q.S Q.S 
7 IPA Q.S Q.S Q.S Q.S Q.S Q.S 
8 % w/w Enteric 
coating 
Solution 
15% 15% 15% 15% 15% 15% 
9 Theoretical 
weight of 
tablets 
 
62.6mg 63.5mg 63.9mg 63.7mg 64.5mg 64.9mg 
10 Final weight of 
tablets  
(Enteric 
Coated) 
63.0mg 63.4mg 64.0mg 64.0mg 64.8mg 64.8mg 
11 % Build up 9% 10% 11% 12% 13% 15% 
 Conclusion Swelling 
was 
observed
DT not 
matched
DT not 
matched
DT 
slightly 
matched
Enetric 
coating 
was 
optimized 
DT not 
matched 
Note – Q.S (Quantity Sufficient) & NOTE: IPA: WATER=80:20 
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Finally the polymer concentration for enteric coating of tablet to pass the all required 
parameters was obtained.  From this was concluded  the final formulation is F5F 
 
6.4.4. Sugar coating solution preparation: 
 
a) Procedure for sugar coating solution: 
 
1. Dispense all the ingredients as per manufacturing formula. 
2. Take required quantity of water and boil it &add slowly HPMC E15 to it until to 
get a    clear solution. 
3. Take required quantity of water &boil it, and add sucrose to it  to get a sucrose 
solution 
4. Shift sucrose solution to HPMC E15 solution and kept in a homogenizer under 
stirring condition. 
5. To the above solution add talc and magnesium stearate and continue stirring for 
45 min. 
6. Filter the solution through #100 and spray the solution with suitable parameters. 
7. Take 2% of sub-coating solution add titanium dioxide, iron oxide yellow under 
stirring condition up to 30min to get color solution. 
8. Filter the solution through #100 and spray the solution with suitable parameters. 
 
b) Sugar coating parameters: Table No. 15 
Coating pan RPM 10 to 20  
Inlet Air Temperature 50 to 60 
Exhaust Air Temperature 47 to 52 
Spray RPM 3 to 10 
Spray  Gun 0.8mm nozzle. 
Atomization Pressure Less than 1.8 kg/cm2 
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b) Sugar Coating- Batch no F5F1-F5F5 
  
                                        Table No 16. Sugar Coating Formulation 
 
S.NO Ingredients Amt mg/tablet 
  Formulation Numbers 
  F5F1 F5F2 F5F3 F5F4 F5F5 
 Sub-coating 
 
     
1 Sucrose 97.5 22.4 22.4 19.04 19.04 
2 HPMC E15 - 6.40 6.40 5.43 5.43 
3 MCC 105 7.31 - - - - 
4 Mannitol 13.0 - - - - 
5 HPMC E5 2.43 - - - - 
6 Talc - 3.2 10.0 8.50 8.50 
7 Magnesium 
Stearate 
- - 1.5 1.28 1.28 
 Color or Smooth coating 
 
8 Opadry yellow  6.25 3.0 - - - 
9 Opagloss Yellow - - 3.5 - - 
10 Iron Oxide Yellow - - - 0.40 0.40 
11 Titanium dioxide - - - 0.065 0.065 
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 Polish Coating 
 
12 Opagloss clear 2 2 - - - 
13 Carnauba Wax - - - 0.50 0.50 
14 IPA - - - Q.S Q.S 
 Conclusion Roughing 
surface, 
color not 
match 
Physical 
appearance 
color not 
matching 
Physical 
appearance 
color not 
matching 
Slightly 
matched 
but color 
not 
matching 
Sugar 
coating 
was 
optimized
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6.5. EVALUTION OF TABLETS38:  
a)  Description:  Poured 10 tablets in to the Petri dish and visualized it manually.  
b)  Weight variation tests: The 20 tablets were selected randomly and weighed. The 
average weights were compared with individual tablet weight. The percentage weight 
variation was calculated. As per British pharmacopoeia specification, tablets with an 
average weight 102 mg, the percentage deviation should not be more than 7.5 %. 
     Table No. 17 – Weight Variation test 
     Average Weight of tablets(mg)      Maximum % difference allowed 
                     Less than 80                            10 
                       80-250                            7.5 
                    Above 250                              5 
 
                                  Tablet Weight-Average weight  
    %Deviation = --------------------------------------------------    x   100 
                                           Tablet Weight 
c)  Friability test:  
Weighed amount of 20 dedusted tablets were subjected to rotating drum of friability test 
apparatus. The drum was rotated at a speed of 25 rpm for 4 minutes and reweighed the 
tablets. % friability was calculated by the following formula. 
100 X 
 weightInitial
 WeightFinal - weight Initial   Friability % =  
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d)  Diameter & thickness: 
Twenty tablets were selected randomly and determined its diameter & thickness by using 
vernier caliper and reading were noted. 
e)  Hardness: 
10 tablets were determined for hardness by using Monsanto hardness tester instrument. 
The force applies up to breaking of tablets. Results were noted down the force required to 
break the tablet. 
f) Acid Uptake Test:  
In this method take 6 tablets and note the initial weight of each tablets and immersed in 
0.1N HCl for 2hrs, after that remove the tablets and dry it and again check the weight i.e., 
final weight. The following formula is used to calculate the % acid uptake of tablets. 
                                          Final weight-Initial weight                                                                                          
   %Acid uptake = ----------------------------------------------- *100 
                                                Initial weight        
 
g)  Disintegration test40-41: 
Placed one tablet in each tube of the basket, using 0.1 N HCl maintained at 370 C±20C as 
immersion fluid for 2 hrs. Noted if the tablets were remaining intact or not. Later placed 
same tablet in each tube of the basket, using different pH phosphate buffer maintained at 
370C±20C as immersion fluid for tablet disintegration. Noted down the time to complete 
disintegration.     
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h) Assay42: 
Determined by liquid chromatography. 
Bisacodyl 5mg Gastro-Resistant Tablets contain not less than 95.0% and not more than 
105.0% of the labeled amount of C22H19NO4 
Solvent mixture.  
4 volumes of glacial acetic acid, 30 volumes of acetonitrile and 66 volumes of water. 
Test solution:  
Weighed and powder 20 tablets. Weighed a quantity of powdered tablet containing 10mg 
of Bisacodyl with 40ml of solvent mixture, dilute to 50ml and filter. Dilute further 1 
volume to 4 volumes with solvent mixture. (0.05% w/v)  
Chromatographic System: A stainless steel column 25cm x 4.6mm packed with 
octadecylsilyl silica gel (5μm). 
Mobile Phase: A mixture of 45 volumes of acetonitrile and 55 volumes of 0.025M 
ammonium formate adjusted to pH 5.0 with anhydrous formic acid.  
Flow Rate: 1.5 ml per minute. 
• Use a detection wavelength of 265nm. 
• Inject 50μl of  each solution.     
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Standard preparation:  
Dissolved an 75mg weighed quantity of Bisacodyl standard in 100ml mixture of 99ml of 
acetonitrile and 1ml of formic acid. (British Pharmacopoeia, 2009) 
Formula for Calculate the % of Assay 
                   Area of Sample             Dilution of Standard              Avg. Wt. of Tab.        Potency                                               
%Assay = -----------------------   X -----------------------------   X --------------------   X -------------------- X 100 
                       Area of Standard        Dilution of Sample                LC                             100 
 
 
Formula for Calculate the % of Impurity: 
 
              Area of impurity     Dilution of dil. Standard    Avg. Wt. of Tab.     Potency        1                                                       
Impurity= ---------------------- X   ----------------------------- X   -------------------- X ---------- X ----      X 100  
                 Area of dil. Standard     Dilution of Sample                        LC                100         RRF                       
 
LC – Label Claim 
RRF- Relative Response factor of impurity. 
 
i ) Dissolution:  
Acid Stage: Dissolution Conditions: 
Apparatus:   Paddle 
Medium Volume:  900ml 
Medium:   0.1M Hydrochloric Acid 
RPM:    100 
Time Interval:  2 hours 
Temperature: 370C+ 0.50C 
 
Buffer Stage: Dissolution Conditions: 
Apparatus:   Paddle 
Medium Volume:  900ml 
Medium:   Phosphate Buffer pH – 6.8, 7.4, 8.0. 
RPM:    100 
Time Interval:  2 hours 
Temperature: 370C+ 0.50C 
 
Chromatographic Conditions:  as per Assay method 
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6.6. STABILITY STUDY9: 
An overall view 
Purpose 
  Stability studies are an integral part of the drug development program and are one 
of the most important areas in the registration of Pharmaceutical products. The purpose of 
stability testing is to provide evidence on how the quality of a drug substance or drug 
product varies with time under the influence of a variety of environmental factors such as 
temperature, humidity and light and enables recommended storage conditions, re-test 
periods and shelf lives to be established. Stability assessment started with studies on the 
substance to determine degradation products and degradation pathway. On the ICH 
Harmonized Tripartite Guidelines on Stability testing of New Drug substances and 
products, fundamental recommendations are summarized. 
According to the ICH guidelines, long term (12 months) and accelerated stability 
studies (at least 6 months) have to be carried out. 
Storage Conditions 
 In general, a drug product should be evaluated under storage conditions (with 
appropriate tolerances) that test its thermal stability and, if applicable, its sensitivity to 
moisture or potential for solvent loss. In general case, how the study done was shown by 
the below Table.18 
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Stability study (General case) 
Table No. 18 - Stability study Conditions 
Study Storage condition 
Minimum time period 
covered by data at 
submission 
Long term 
25°C ± 2°C/60%RH ±5% 
RHor30°C ± 2°C/65%RH ±5% 
RH 
12 months 
Intermediate 30°C ± 2°C/65%RH ±5% RH 6 months 
Accelerated 40°C ± 2°C/75%RH ±5% RH 6 months 
 
It is up to the applicant to decide whether long term stability studies are performed 
at 25°C ± 2°C/60%RH ±5% RH or   30°C ± 2°C/65%RH ±5% RH . If 30°C ± 
2°C/65%RH ±5% RH is the long term condition, there is no intermediate condition. If 
long term studies are conducted at 25°C ± 2°C/60%RH ±5% and significant change 
occurs at any time during 6 months testing at the accelerated storage condition, additional 
testing at   the intermediate storage condition should be conducted and evaluated against 
significant change criteria. 
 For drug products packaged in impermeable containers (Aluminum tubes), semi 
permeable container ( LDPE pouches, bottles etc), drug products intended for storage in a 
refrigerator , in a freezer and below –20°C, the study , storage condition and minimum 
time period covered by data at submission, are different not like as in general case. (ICH 
Q 1A9 R2 Stability testing guidelines) 
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Testing Frequency 
 For long term studies frequency of testing should be sufficient to establish the 
stability profile of the drug product. For products with a proposed shelf life of at least 12 
months, the frequency  of testing at the long term storage condition should normally be 
every 3 months over the first year, every 6 months over the second year and annually 
thereafter through the proposed shelf life.  
At the accelerated storage condition, a minimum of three time points, including the 
initial and final time points (e.g. 0,3 and 6 months) , form a 6- month study is 
recommended.  
When testing at the intermediate storage condition is called for as a result of 
significant change at the accelerated storage condition , a minimum of  four time points 
including the initial and final time points (e.g. 0, 6, 9, 12 months) form a 12 month study 
is recommended.  
Joel Davis test 
 According to Joel Davis Test , if the  product holds up for 3 months under 
accelerated condition i.e. 40°C and 75%RH (chemical stability, dissolution , physical 
characteristics ) , then in an ANDA , the generic company will be given a two year 
expiration date  but must follow up with real time data to substantiate the dating . The 
method is however, also used by ethical companies in the development of new drug 
entities. If the product does not pass the Joel Davis test, then conventional stability testing 
at room temp for prolonged periods (eighteen months) must accompany the NDA or the 
ANDA to satisfy the stability requirements of the submission. 
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Generally Acceptable Design considerations for Tablets and Capsules  
Tablets: A stability study should include tests for the following characteristics of the 
tablet: Appearance, friability, hardness, color, odor, moisture, strength and dissolution. 
Capsules: A stability study should include tests for the following characteristics, 
strength, moisture, color, appearance, shape, brittleness, and dissolution.( ICH Q 1A9 R2 
Stability testing guidelines) 
Procedure: 
Packing material: Alu- PVDC blisters Packing. 
Bisacodyl 5mg Gastro-resistant Tablets were exposed at: 40O C/75% RH, 50O C/75%RH 
conditions 
The Tablets were withdrawn and analysed for following parameters: 
• Physical parameters of Tablets   
• Related substances 
• Assay (ICH Q 1A9 R2 Stability testing guidelines) 
• Dissolution 
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7.0. RESULTS  AND DISCUSSION 
7.1. REVERSE ENGINEERING OF REFERENCE PRODUCT & 
COMPARISON WITH TEST PRODUCT 
PARAMETERS RESULTS 
 Reference Product Test Product 
Product Dulcolax Bisacodyl 5 mg Gastro-
resistant  
Tablets 
Description 
Yellow colored biconvex  
Shaped tablets, plain on both 
the sides. 
Yellow colored biconvex  
shaped tablets, plain on both 
the sides 
 
Lot Number: 018973 BGR-TX0005-F005 
Expiry date: June 2013 Not Applicable 
Manufactured  
Boehringer Ingelheim 
Limited, France 
Genovo Development 
Service Ltd 
 
STAGE 1 : FINISHED PRODUCT 
 
PARAMETERS RESULTS 
Description Reference Product Test Product 
Yellow coloured biconvex 
shaped  
Tablets, plain on both the sides. 
Yellow coloured biconvex 
shaped  
tablets, plain on both the sides. 
 
Weight 97.5 mg 98.456 mg (theoretical target 
weight)  
Thickness 3.52 mm 3.77mm 
Diameter 5.95 mm 5.90mm 
 
Fig.6 Photograph 
of the Tablet 
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STAGE 2 : TABLET WITH ENTERIC COATING (AFTER 
DISSOLVING OUTER SUGAR COATING LAYER) 
 
PARAMETER
S 
RESULTS
Description Reference Product Test Product 
White biconvex tablet with the waxy 
appearance or little shiny appearance.
White biconvex tablet with shiny 
appearance
Weight 76.4 mg 63.25mg
Thickness 3.19 mm 3.16mm
Diameter 5.65 mm 5.31mm
Inference  The mean sugar coating weight may 
contributes to 25 mg – 30 mg.  
The mean sugar coating (sub 
coating with color coating & 
polishing) weight Contributes 
35.215mg.
Fig.7 
Photograph  
of the 
Tablet 
 
STAGE 3:  TABLET AFTER REMOVAL OF ENTERIC COATING LAYER 
 
PARAMETER
S 
RESULTS 
Description White biconvex tablet with 
the waxy appearance  
White biconvex tablet with 
the shiny appearance 
Weight 62.5 mg 57.5mg
Thickness 2.80 mm 3.07mm
Diameter 5.37 mm 5.19mm
Inference The mean enteric layer 
weight may contribute to 14 
mg – 15 mg. The core with  
the seal coating layer may 
contributes to  
weight of 62 to 65 mg. 
The mean enteric layer 
weight contributes to 5.75 
mg. The core with the seal 
coating layer may 
contributes to weight of 57.5 
mg. 
Fig.8  
Photograph  
of the Tablet 
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STAGE 4 :  DISINTEGRATION OF THE ABOVE TABLET IN 
PURIFIED WATER     (i.e. Tablet after removing the enteric layer) 
PARAMETERS RESULTS 
 Reference Product Test Product 
Description The DT of the above tablet shows 
that there is a presence of another 
layer which was peeled of during 
the agitation on the media (water) 
using a spatula. The film layer is 
seen in the photograph below. The 
time taken by the film to break was 
3’30” sec (Figure 1).After the 
removal of the film the tablet 
disintegrated completely with in a 
minute. (Figure 2). 
DT of the seal tablet shows 
that film layer disintegrates 
same pattern as reference 
product and the time taken by 
the film to break was 4’04” sec 
(Figure 1). 
After the removal of the film 
the tablet disintegrated 
completely with in a 40 secs. 
(Figure 2). 
Media/ Volume  100 ml water  
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Photograph of Disintegration of the Tablets 
 
 
 
 
 
 
 
Fig: 9 
  
 
 
Fig:10 
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7.2. PREFORMULATION STUDY38:  
 7.2.1. Organoleptic Properties  
These test performed as per procedure given in experimental work chapter and results 
are illustrated in following table. 
                             Table No. 19: Organoleptic properties: 
Test Specification Observation 
Color White crystalline powder. White, crystalline powder 
Taste Tasteless Tasteless 
Odour Odourless Odourless 
  
The above result shows all parameters are within Specification 
  7.2.2. Loss on drying: 
 These test performed as per procedure given in experimental work chapter the results 
are illustrated in following table. 
                                              Table No 20.  Loss on drying 
Test Specification Observation 
Loss on drying  Not more than 0.5% 0.18% 
 
The above result shows all parameters are within Specification 
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7.2.3. Angle of Repose: 
These test performed as per procedure given in experimental work chapter. The 
results are illustrated in following table 
                          Table No 21.   Angle of Repose- API 
Sr. No. Material Angle of repose Average angle of repose 
1  
API 
83.70  
830.52’ 2 83.09 
3 83.79 
 
 
7.2.4. Bulk Density and tapped density:  
These test performed as per procedure given in experimental work chapter. The 
results are illustrated in following table. 
Table No. 22:  API - Bulk Density and tapped density 
S.No. Material Bulk density (gm/cc) 
Average 
bulk 
density 
(gm/cc) 
Tapped 
density 
(gm/cc) 
Average 
tapped 
density 
(gm/cc) 
1  
API 
0.21  
0.20 
0.28  
0.32 2 0.20 0.33 
3 0.20 0.35 
 
 
                                                                                  Results and Discussion 
Department of Pharmaceutics, R.V.S. College of Pharmaceutical Science 
 
89
 
Table No. 23: Blend - Bulk Density and tapped density 
S.No. Material Bulk density (gm/cc) 
Average 
bulk 
density 
(gm/cc) 
Tapped 
density 
(gm/cc) 
Average 
tapped 
density 
(gm/cc) 
1  
Blend 
0.6  
0.6 
0.8  
0.84 2 0.59 0.85 
3 0.61 0.88 
  
The bulk density and tapped density of active material and blend ready for 
compression were determined and calculated by using the formula, 
 
                                   Weight of substance                
Bulk density = -------------------------------------------   (gm/cc) 
                                Final volume of substance                                                                      
 
                                                           Weight of substance 
 
                     Tapped density = ---------------------------------------------   (gm/cc)      
                                 Final volume of substance after tap                                
 
The above result shows that drug have low density.  
7.2.5. Compressibility index: 
These test performed as per procedure given in experimental work chapter. The 
results are illustrated in following table. 
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                                           Table No 24. Compressibility index 
Material Compressibility index Hausner ratio 
API 42.86 1.75 
                 The above result shows that drug has very poor compressibility index. 
                                        Table No 25.Sieve analysis:     
Sieve no Empty 
sieve(gm) 
Sample 
sieve(gm) 
Weight of 
sample 
      (gm) 
%Retained %Cumulative 
Retained 
#40 399.8 420.6 20.8 51.23 51.2 
#60 393.4 412.2 18.8 46.30 97.5 
#80 383.8       384.2         0.40 0.985 98.5 
#100 384.4       384.4 0.40 0.985 99.5 
#120 376.4 376.6 0.20 0.492 99.9 
#140 374.8 374.8          0            0          99.9 
#200 374.4 303.2          0   0 99.9 
Receiver 377.4 359.0           0   0 99.9 
 
Weight of sample=41.0gm. 
 
NOTE: Agglomerates are formed. 
 
7.2.6. pH: 
These test performed as per procedure given in experimental work chapter. The 
results are illustrated in following table. 
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Table No. 26 pH of API 
Test Specification  Observation 
           Bisacodyl 6-7 7 
 
The above result shown all parameters complies. 
 
7.2.7. Melting Point: 
These tests were performed as per procedure given in experimental work chapter. The 
results are illustrated in following Table No.27 
                                              Table No 27. Melting Point of API 
S.No. Material Melting point range 
1 Bisacodyl 131-135°C 
 
The result of table indicates that the Bisacodyl was pure one. 
 
7.2.8. Drug-excipient compatibility study:  
It was determined as per procedure given in experimental work chapter.  The results 
are illustrated in following Table 
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Table No 28. Drug-excipient compatibility study 
Sr. 
No. 
Name of the Excipient  
+ drug Initial 
Exposed to 
250C/60% 
RH 
Exposed to 
500C/75% 
RH 
Comment 
1 Drug X White  color No change No change Compatible 
2 API + Lactose 
monohydrate White color 
No change No change Compatible 
3 API + Maize starch White color No change No change Compatible 
4 API +Pregelatinized 
starch  White color 
No change No change Compatible 
5 API + Talc White color No change No change Compatible 
6 API + Magnesium 
stearate 
White color White color No change Compatible 
7 API +HPMC E5  White color No change No change Compatible 
8 API + Eudragit 
L100&S100 White color 
No change No change Compatible 
9 API + HPMC 15 cps White color No change No change Compatible 
10 API + TEC White color No change No change Compatible 
11 API+ Titanium dioxide White color No change No change Compatible 
12 API + Sucrose White color No change No change Compatible 
13 API + Iron oxide 
yellow 
Yellow 
color 
No change No change Compatible 
14 API+ Carnauba wax White color No change No change Compatible 
15 API+  Opadry yellow Yellow 
color 
No change No change Compatible 
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7.3. FORMULATION TABLE RESULTS: 
F=Formulation 
F1-> This trial is to check the physical feasibility of ingredients with the reference 
product. 
F2-> In this trial Direct Compression technique was used and capping is observed due 
to high content of lubricant. 
F3-> The granules are shifted through #24, but UOD was not in a specific limit.. 
Sticking observed due to Humidity 
F4-> Humidity Adjusted to 50% by dehumidification. In this trial UOD is not in a 
specific limit. 
F5-> In this trial we consider the direct compression method, by increasing the % of 
binding agent, proper hardness was observed. 
F5A-> In this trial seal coating was optimized. 
F5B-> In this trial 7% of enteric coating solution was considered, but swelling of 
tablets was observed. Hence enteric coating is further optimized to get better gastric 
resistance. 
F5C-> In this trial 9% of enteric coating solution was considered, but DT is not 
optimized when compared to the reference product. 
F5D-> In this trial 10% of enteric coating solution was considered, but DT is not 
optimized when compared to the reference product. 
F5E-> In this trial 11% of enteric coating solution was considered. DT was slightly 
matched with the reference product by showing 10-11 minutes variation. 
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F5F-> In this trial 13% of enteric coating solution was considered. DT was optimized 
with the reference product.  
 
CONCLUSION: 
By the above trials we observed that F5E & F5F DT was matched with the reference 
product, among them F5F was optimized for enteric coating. 
 
SUGAR COATING:  
F5F1-> In this trial required % of sugar coating solution was considered, but the 
tablet surface was found rough, particles was settled at the edges of tablets. Hence 
sugar coating needs to be optimized. 
F5F2-> In this trial % of sugar coating solution was taken, but physical feasibility 
was not matching with the reference product. 
F5F3-> In this trial % of sugar coating solution was taken, but physical feasibility 
was not matching with the reference product. 
F5F4-> In this trial sugar coating was slightly matching with the reference product, 
but color coating needs to be optimized. 
F5F5-> In this trial sugar coating was optimized. 
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7.4. EVALUATION OF TABLETS - RESULTS: 
7.4.1. FOR CORE TABLET38: (BATCH NO F1-F5) 
a) Description: 
It was determined as per procedure given in Evaluation of tablets in experimental 
work chapter. The following table illustrated the result. 
It is a yellow colored, circular, biconvex tablets. 
b) Individual Weight variation Test: 
It was determined as per procedure given in Evaluation of tablets in experimental 
work chapter. The following table illustrated the result. 
Table No.29: Weight variation Test of Core Tablet 
51.2 50.0 49.8 50.1 50.4 
50.2 50.7 50.0 49.9 50.0 
50.3 50.1 50.4 50.0 49.8 
50 50.4 50.1 50.1 50.0 
Weight of 20 tablets = 869.5mg. 
Average wt of tablet =  102.4 mg. 
Minimum wt of tablet = 50.0mg.
Maximum wt of tablet = 50+2mg. 
The above result show all parameters complies 
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c) Friability: 
It was determined as per procedure given in Evaluation of tablets in experimental 
work chapter. The following table illustrated the result. 
                                Table No. 30 - Friability of Core Tablet 
 Friability in %w/w= (W1 – W2) X 100/W1 (Limit NMT 1.0%) 
Before rotation 
(W1)  
 After rotation (W2) Friability in % 
6.808gm 6.799gm 0.12 
 
The above result shows that the tablets have good mechanical strength 
d) Thickness of core tablet: 
 It was determined as per procedure given in Evaluation of tablets in experimental 
work chapter. The following table illustrated the result. 
                                Table No. 31:  Thickness of 20 tablets in mm 
2.3 2.37 2.37 2.39 2.38 2.38 2.3 2.40 2.39 2.40 
2.35 2.32 2.34 2.4 2.38 2.32 2.36 2.37 2.3 2.36 
 
Maximum Thickness = 2.40 mm. 
Minimum Thickness = 2.30mm. 
The above result shows the tablet diameter. 
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e) Diameter of core tablets:  
It was determined as per procedure given in Evaluation of tablets in experimental 
work chapter. The following table illustrated the result. 
                      Table No. 32:     Diameter of 20 tablets mm 
5.02 5.04 5.06 5.04 4.95 4.99 4.98 5.01 5.00 5.01 
4.96 4.98 4.97 4.99 5.00 4.98 4.96 5.00 4.98 5.00 
Maximum Diameter =5.00 mm. 
Minimum Diameter = 4.90 mm. 
The above result shows that the tablets have uniform thickness. 
 
f) Hardness of core tablets: 
It was determined as per procedure given in Evaluation of tablets in experimental 
work chapter. The following table illustrated the result. 
                                   Table No. 33:  Hardness of tablets 
Hardness of 10 tablets in kp 
2.1 2.9 3.2 3.4 3.4 3.6 3.0 4.0 2.7 3.6 
Maximum Hardness = 4 kp 
Minimum Hardness = 2.5 kp 
The above result shows that the tablets have good mechanical strength. 
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g) Disintegration41-42: 
It was determined as per procedure given in Evaluation of tablets in experimental 
work chapter. The following table illustrated the result. 
Medium: Purified water 
Time limit: within 30 minutes 
Apparatus: disintegration tester (USP)  
                                            Table No. 34:   Disintegration Test 
                                
           The above result shows that the tablets disintegrate within time limit. 
  
h) Assay42 :( Estimation of Bisacodyl by liquid chromatography)  
It was determined as per procedure given in Evaluation of tablets in experimental 
work chapter. The following table illustrated the result. 
Bisacodyl was estimated as per procedure given in method section, the following 
table illustrated the result. 
Limit: Bisacodyl Gastro-resistant tablets contain not less than 95.0 percent and not 
more than 105.0 percent of the labeled amount of C22H19NO4 
 
Disintegration  time 10-15 sec. 
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Table No. 35:  Estimation of Bisacodyl Core Tablet 
Sample 
No. 
Weight 
of 
sample 
(mg) 
Area of 
Bisacodyl peak 
from assay 
preparation 
chromatogram 
%of 
Bisacodyl 
Average %   
Of 
Bisacodyl 
1 50.10 2265739 100.0 100.0 
2 50.10 2261809 100.0 100.0 
 
The above result shows that tablets have uniformity in content. 
Fig.11.Assay Standard - Chromatogram 
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Fig.12.Assay Test - Chromatogram 
 
 
FOR CORE TABLET BATCH (F1 TO F5): 
It was determined as per procedure given in Evaluation of tablets in experimental 
work chapter. The following table illustrated the result. 
Table No.36: Evaluation of core tablets 
 
Parameters  
Formulation No. 
F1 F2 F3 F4 F5 
Average Weight of core tablet (mg) 50mg 50mg 50mg 50mg 50mg 
Weight for 20 tablets(gm)      
Diameter (mm) 5.0 4.98 4.9 5.0 5.0 
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Thickness (mm) 2.4 2.3 3.2 3.2 3.6 
Friability (%) 0.163 0.517 0.264 0.337 0.12 
Hardness (Kg/cm2) 2.4 3.3 2.9 3.2 3.0 
Disintegration time (sec) 
(Purified  water)  
7sec 33sec 10sec 12sec 8sec 
The above F5 batch result shows all parameters complies. 
7.4.2. FOR ENTERIC COATED TABLETS: 
It was determined as per procedure given in Evaluation of tablets in experimental 
work chapter. The following table illustrated the result. 
                Table No.37: Evaluation of Enteric coated tablet 
 
Parameters  
Formulation No. 
F5B F5C F5D F5E F5F 
Average Weight 
(mg) 
61.5mg 62.mg 63.5mg 63.9mg 64.9mg
Weight for 20 
tablets (gm) 
     
Diameter  (mm) 5.36 5.40 5.39 5.41 5.32 
Thickness (mm)  3.15 3.17 3.15 3.17 3.17 
The above result shows all parameters of F5F batch are complies. 
Evaluation for Enteric Coated Tablet :( Formulation No.F5F) 
a) Individual Weight variation of 20 tablets (mg) 
It was determined as per procedure given in Evaluation of tablets in experimental 
work chapter. The following table illustrated the result. 
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Table No. 38: Weight variation of Enteric Coated Tablet (mg) 
  
64.9 64.5 64.9 65.0 64.8 
64.8 64.9 64.9 65.0 64.7 
64.9 65.0 65.1 64.8 64.9 
64.7 64.7 64.8 64.9 64.9 
 
Weight of 20 tablets = 2296 mg 
Average wt of tablet =  114.8 mg 
Minimum wt of tablet = 115.7 mg 
Maximum wt of tablet = 112.7 mg 
Appearance of all tablets = white colored, circular, biconvex enteric coated 
tablets. Above result shows tablets were uniform in weight. 
 
 
b) Diameter of 10 tablets in(mm): 
It was determined as per procedure given in Evaluation of tablets  in experimental 
work chapter . The following table illustrated the result. 
 
Diameter of Tablet 
5.27 5.32 5.32 5.27 5.26 5.30 5.31 5.32 5.32 5.32 
Maximum Diameter = 6.65 mm 
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7.4.3. EVALUATION FOR SUGAR COATED TABLET:                          
(FORMULATION NO.F5F5)  
a) Individual Weight variation of 20 tablets (mg) 
It was determined as per procedure given in Evaluation of tablets in experimental 
work chapter. The following table illustrated the result. 
 
 
Minimum Diameter = 6.63 mm 
The above result shows that tablet  have uniformity in diameter 
c) Thickness  of 20 tablets (mm)  
It was determined as per procedure given in Evaluation of tablets in  experimental 
work chapter . The following table illustrated the result. 
                                                           Thickness  of Tablets 
3.15 3.15 3.17 3.17 3.15 3.16 3.18 3.20 3.17 3.17 
3.18 3.15 3.17 3.20 3.20 3.17 3.18 3.15 3.17 3.17 
Maximum Thickness = 3.55 mm 
Minimum Thickness = 3.45 mm 
The above result shows that the tablet has uniformity in thickness. 
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                      Table No. 39: Weight variation of Sugar Coated Tablet (mg) 
  
97.2 100.8 101.2 97.3 94.1 
97.2 100 100.3 100.2 101.1 
99.8 99.9 101 100 100.5 
99.9 100 100.4 100.2 100.1 
 
Weight of 20 tablets = 2296 mg 
Average wt of tablet =  114.8 mg 
Minimum wt of tablet = 115.7 mg 
Maximum wt of tablet = 112.7 mg 
Appearance of all tablets = white colored, circular, biconvex enteric coated 
tablets. Above result shows tablets were uniform in weight. 
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b) Diameter of 10 tablets in(mm): 
It was determined as per procedure given in Evaluation of tablets in  experimental 
work chapter . The following table illustrated the result. 
                                           Diameter of Tablet 
5.94 5.89 5.88 5.90 5.89 5.91 5.94 5.93 5.89 5.91 
Maximum Diameter = 6.65 mm 
Minimum Diameter = 6.63 mm 
The above result shows that tablet  have uniformity in diameter 
c) Thickness  of 20 tablets (mm)  
It was determined as per procedure given in Evaluation of tablets in  experimental 
work chapter . The following table illustrated the result. 
                                                  Thickness  of Tablets 
3.80 3.77 3.79 3.80 3.77 3.78 3.76 3.79 3.78 3.75 
3.79 3.80 3.79 3.77 3.77 3.78 3.79 3.80 3.80 3.79 
Maximum Thickness = 3.55 mm 
Minimum Thickness = 3.45 mm 
The above result shows that the tablet has uniformity in thickness. 
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d) Disintegration40: 
It was determined as per procedure given in Evaluation of tablets in experimental 
work chapter. The following table illustrated the result. 
Acid Medium: 
Medium: Acid (0.1N HCl Purified 800ml). 
Time limit: Tablets remain intact for 120 minutes. 
Apparatus: Disintegration Tester (USP).  
Table No. 40: Disintegration in Acid Medium of Enteric coated tablet 
Disintegration  time Tablet remain intact for 120 min. 
 
 
 
The above result shows that tablet doesn’t disintegrate in acidic pH 
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Disintegration of Different percentage of Enteric coated tablet in 
Phosphate Buffers 
Table No. 41: 
 
 
Fig.13. Disintegration of 9-15% Enteric Coated Tablet 
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Note: All disintegration tests are performed in 0.1N HCl for 2 hours followed by Phosphate 
buffer. 
 
The above result shows that Innovator and 13% Enteric coated Bisacodyl Tablet has similar  
Disintegration time in  Phosphate Buffer pH 6.8- to pH -8.0  
 
 
 
 
 
 
Media 
Disintegration time in Minutes 
0.1N HCl PHOSPHATE 
BUFFER Reference Product 
Test 
Product 
(9%) 
Test 
Product 
(10%) 
Test 
Product 
(12%) 
Test 
Product 
(13%) 
Test 
Product  
(15%) 
 
 
0.1N HCl    
(2hrs) 
6.8 120 83 88 99 118 150 
7.0 91 72 77 81 89 100 
7.2 49 34 36 41 50 62 
7.4 41 30 32 34 42 50 
7.6 29 20 21 24 30 39 
7.8 23 19 20 21 23 26 
8.0 22 12 14 16 22 25 
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e) Dissolution43-45 
 
• Dissolution of Different percentage of Enteric coated tablet in 
Phosphate Buffers 
 
Table No. 42: Phosphate buffer pH-6.8 
 
 
 
Sno. Enteric 
coating 
% 
  
0.1N 
Hcl 
  
  
  
   
 
 
2hrs 
  
  
  
  
   % Release ↓                         Range (min) → 
0 30 60 90 120 150 180 
1 9% 0 2.40 7.40 35.60 80.30 101.20 102.40 
2 10% 0 2.00 6.90 33.51 74.42 101.80 102.69 
3 12% 0 1.75 6.00 30.10 61.20 99.22 102.32 
4 13% 0 1.50 5.60 22.55 39.58 79.45 101.81 
5 15% 0 1.37 3.75 15.87 20.39 34.48 88.99 
6 Innovator 0 1.10 4.30 21.37 41.71 82.22 100.36 
 
 
   Fig.14. Dissolution of 9-15% Enteric Coated Tablet in pH-6.8 Phosphate buffer 
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The above result shows that Innovator and 13% Enteric coated Bisacodyl Tablet  has 
similar  release patterns in Phosphate Buffer pH 6.8 
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                               Table No. 43: Phosphate buffer pH-7.4 
 
 
Sno. Enteric 
coating 
% 
  
0.1N 
Hcl 
  
  
  
  2hrs 
  
  
  
   % Release ↓                         Range (min) → 
0 30 60 90 120 150 180 
1 9% 0 47.20 88.30 102.20 102.40 101.50 101.40 
2 10% 0 33.55 79.70 101.86 101.46 101.80 101.69 
3 12% 0 27.64 71.20 101.30 101.20 101.41 101.32 
4 13% 0 20.46 60.70 100.35 101.58 101.79 100.69 
5 15% 0 10.40 44.50 98.30 100.39 101.48 100.39 
6 Innovator   0 18.40 62.30 99.44 100.02 101.1 99.8 
 
 
 
Fig.15 Dissolution of 9-15% Enteric Coated Tablet in pH-7.4 Phosphate buffer 
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The above result shows that  Innovator and 13% Enteric coated Bisacodyl Tablet  has 
similar  release patterns in Phosphate Buffer pH 7.4 
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                               Table No. 44: Phosphate buffer pH-8.0 
 
 
Sno. Enteric 
coating 
% 
  
0.1N 
Hcl 
  
  
  
  2hrs 
  
  
  
  
   % Release ↓                         Range (min) → 
0 30 60 90 120 150 180 
1 9% 0 54.25 101.49 101.10 102.28 101.33 101.24 
2 10% 0 38.56 91.61 101.24 101.52 101.28 101.29 
3 12% 0 31.77 81.84 100.10 101.27 101.54 101.32 
4 13% 0 23.52 65.20 98.90 101.38 101.47 100.42 
5 15%   11.95 51.15 97.53 100.29 101.61 100.29 
6 Innovator 23.01 23.01 67.10 100.34 101.61 101.20 100.84 
 
 
 
 
 
 
Fig.16 Dissolution of 9-15% Enteric Coated Tablet in pH-8.0 Phosphate buffer 
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The above result shows that  Innovator and 13% Enteric coated Bisacodyl Tablet  has 
similar  release patterns in Phosphate Buffer pH 8.0 
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Table No. 45 f2 and f1 values for dissolution of F5F (13%) vs Innovator 
 
Medium f2 f1 
0.1 N HCl - pH 1.2 95.14 0.35 
Phosphate buffer - pH 6.8 97.08 0.68 
Phosphate buffer - pH 7.4 91.77 0.76 
Phosphate buffer - pH 8.0 94.60 0.49 
f1 (Dissimilarity Factor) = NMT 15 
f2 (Similarity Factor)  = NLT 50 
 
f) Related Substance (RS): 
 
It was determined as per procedure given in Evaluation of Tablet in Experimental 
work chapter. The following table illustrated the result. 
Bisacodyl was estimated as per procedure given in method section, the following 
table illustrated the result. 
Fig.17 Initial RS for Core Tablet – Chromatogram 
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Fig.18 Initial RS for Final coated tablets– Chromatogram 
 
The RS results are within the limits 
 
 
 
7.5. STABILITY STUDY RESULT:  
(For Formulation No: F5F5)11-13 
 a) DESCRIPTION:     
It was determined as per procedure given in Evaluation of tablets in Experimental 
work chapter. The following table illustrate the result.             
         Table No.46: Stability Description of Final Product – Color Coated Tablet 
S.No. Storage condition Period  
 
Appearance 
 
1 
250C±20C /60%±5%RH 
& 
400C±20C /75%±5%RH 
 
1 months 
Yellow colored , 
biconvex ,circular 
shape Intact.   
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b) ASSAY:  
It was determined as per procedure given in Evaluation of tablets in Experimental 
work chapter. The following table illustrated the result. 
Table No.47: Assay- 1 Month Stability 
Storage  
Condition  
Storage 
 period  
Specification Inference  
250C±20C /60%±5%RH 
& 
400C±20C /75%±5%RH 
1months NLT 95.0% and NMT 
105.0% of labeled amount 
of -- 
 
100.52% 
 
Fig.19 RS for Final Product at 250C /60%RH, 1 Month Stability Conditions 
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Fig.20  RS for Final Product at 400C /75%RH, 1 Month Stability Conditions 
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Fig.21 RS for Final Product at 500C /75%RH, 1 Month Stability Condition 
 
 
Table No.48 – Related substance of Final Product at 250C /60%RH, 400C 
/75%RH, 1 Months (Stability Studies) and 500C /75%RH, 1 month (Degradation 
Study) 
S.NO RELATED SUBSTANCE LIMITS 
1 IMP A,B NMT 0.1%
2 IMP C,E NMT 0.5%
3 IMP D NMT 0.2%
4 IMP F NMT 0.3%
5 UNSPECIFIED IMPURITIES NMT 0.1%
6 DISREGARD IMPURITIES NMT 0.05% 
7 TOTAL IMPURITIES NMT 1.0%
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 7.6. DISCUSSION 
 The objective of the study is to formulate and evaluate Bisacodyl Gastro-
resistant tablets compared to the innovator product. 
   Formulations of  enteric coated and sugar coated tablets of Bisacodyl were 
developed by preparing core tablets using Lactose monohydrate as diluent and 
Pregelatinized starch as binder and varying the compositions of enteric coating using  
Eudragit, and sugar coating using HPMC E15, titanium dioxide. The core tablets were 
prepared by direct compression method. 
    The results indicated that the finished product formulations F5F fulfilled all 
the specifications of the physical properties and chemical properties are comparable to 
the innovator product. Formulation F2 failed to compress as tablets due to capping 
problem. In Formulation F5B acid resistance test was failed due to insufficient enteric 
coating. Enteric coated formulations F5C to F5E Disintegration test was not matched 
when compared to the reference product.   
      Enteric coated formulation F5F fulfilled all the specifications prescribed 
for Bisacodyl Gastro-resistant tablets and comparable to the innovator product  
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8.0. SUMMARY AND CONCLUSION 
SUMMARY 
The objective of present work is to formulate and evaluate Gastro-resistant Tablet of bisacodyl.  
The present work aims to avoid degradation of drug in acidic environment of stomach. So due to 
enteric coating drug releases in to the small intestine so that peristaltic movement occurs. 
Preformulation studies were compared with British pharmacopoeia (BP) specification for 
Bisacodyl. The physical properties such as Organoleptic characteristics, loss on drying, angle of 
repose, compressibility, density, solution properties like pH, melting point of the solution were 
evaluated.  
Drug excipients compatibility study performed at 25oC /60% RH and 50OC/75% RH for 1month.  
The physical and chemical compatibility was determined.  
Lactose monohydrate, Pregelatinized starch are used to prepare a blend for direct compression 
method. The prepared blends were lubricated with Magnesium stearate. To protect the drug form 
degradation in acidic environment tablet formulation coated with pH dependant solubility 
polymers Eudragit L100 & S100 (Enteric coating polymer). 
Blends were compressed on tablet compression machine by using 5 mm punch.  Finally 
optimized formulation for core tablet i.e. F5 is obtained. It gives all required parameters for core 
tablet. F5 formulations were selected for seal coating and finally enteric coating with Eudragit 
having optimized polymer 13% coating. 
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These selected formulations were evaluated for tablet parameters i.e.  Weight variation, diameter 
& thickness, hardness, disintegration in 0.1 M HCl for 120 min and different phosphate buffers 
was used, pH-7.6 phosphate buffer showed better disintegration of tablet.  
Assay performed by HPLC method to determine content of drug per tablet and related substance 
also performed by HPLC method. 
Alu-P.V.D.C blister strip used as packing material. This finally packed tablet kept for stability 
at different storage condition. 
Stability studies were carried out for optimized formulation at 250C /60%RH, 400C /75%RH, 1 
Months (Stability Studies) and 500C /75%RH, 1 month (Degradation Study). After completion of 
time period, assay and related substance for every storage condition was determined. On 
completion of all the study, selected formulation was decided as a final product which complies 
with reference product parameters. 
                             Summary and Conclusion 
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8.0. CONCLUSION 
 
Preformulation results comply with Pharmacopoeial specification. 
 
Drug-Exipients compatibility studies found that API was compatible with the excipients and test 
results directs the further development of formulation. 
 
Bisacodyl core tablet was made by direct compression techniques and optimized using 
Pregelatinized starch as Binder – (Formulation F5).  
  
A seal coat of 15% weight gain using H.P.M.C.-5cps (Formulation F5A) was sufficient to protect 
the tablets from the acid coat of the enteric layer.  
 
Enteric coating was done using Eudragit L100: Eudragit S100 (1:3 ratios) to achieve 9, 10, 11, 
12, 13 and 15% weight gain. Formulation F5F with 13% enteric coating found similar with 
innovator by the results. 
 
Sugar coating and Color coating Formulation F5F5 optimized to achieve the Physical feasibility. 
 
Disintegration time for Innovator and 13% enteric coating found similar in 0.1N HCl for 2 hours 
and Phosphate buffer pH – (6.8 – 8.0).  
 
Dissolution of Innovator and 13% enteric coating in 0.1N Hydrochloric acid – 2 hours and 
Phosphate Buffer pH – 6.8, 7.4, 8.0 found similar with f1 – NMT15 and f2 – NLT50. 
 
Bisacodyl Gastro-resistant (Enteric coated) Tablet with packing materials Alu- PVDC blisters 
Packing found as stable formulation in different stability conditions. After the stability study all 
physical, assay, related substance, and dissolution test have done and shows no change compared 
to the initial test.  
 
Based on the results of different trials, F5F5 formulation is satisfactory and can be taken for 
Scale-Up and Bio-Study 
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